



THE ARTHRITIS RESEARCH CANADA
BOARD MEETING – THURSDAY, SEPTEMBER 10, 2020
ANNUAL REPORT OF THE SCIENTIFIC DIRECTOR

Trainees

Arthritis Research Canada Richmond welcomed two new trainees in September 2019. **Nejat Hassen** (Supervisors: **Diane Lacaille** and **Jacek Kopec**) is completing her Master's and is investigating '*Geographic disparities in burden of disease from rheumatoid arthritis*', and **Olubayo Kolawole** (Supervisor: **Antonio Aviña**) is a PhD student whose project is on '*Hydroxychloroquine toxicity in rheumatoid arthritis and systemic lupus erythematosus*'.

Laurence Mainville (Supervisor: **Paul Fortin**) joined Arthritis Research Canada/Arthrite-recherche Canada Laval in September. Her thesis project is '*Retrospective cohort study comparing disease severity in psoriasis treated with biotherapy under a public or private drug insurance plan*'.

Miriam Dessay (Supervisor: **Laetitia Michou**) is a new PhD trainee at the Arthrite-recherche Canada Laval centre. Her research focus is on Paget's disease of bone.

Megan Thomas is a new Master's level trainee at Arthritis Research Canada Calgary (Supervisors: **Glen Hazlewood** and **Deborah Marshall**). Her project title is "*Developing guidance on preference-based methods in clinical trials to value health outcomes in rheumatic diseases: a mixed methods study*."

Bryanne Kennedy (Supervisor: **Deborah Marshall**) is a new Master's Trainee at Arthritis Research Canada Calgary. Her thesis work aims to "*quantify patient preferences for the non-surgical management of osteoarthritis, and explore the relationship between those preferences and health locus of control*".

Trainees were actively involved in presenting their research at the Arthritis Research Canada/Arthrite-recherche Canada's monthly Research Webinar.

Elly Park (Supervisor: **Allyson Jones**) presented in October 2019 on "*Living with osteoarthritis and obesity: sharing patient perspectives through digital storytelling*"

Jasmin Ma (Supervisor: **Linda Li**) presented in November 2019 on "*ISTART Improving strength training in people with rheumatoid arthritis*".

Rashed Hoque (Supervisor: **Hui Xie**) presented in February 2020 on "*How Antimalarials Adherence Affects the Mortality of Lupus Patients? A Population-based Study*".

Kiera Lee-Pii (Supervisor: **Diane Lacaille**) presented in May on "*Physical activity levels among rheumatoid arthritis patients compared to the general population and its association with Disease Activity*."

SUMMER STUDENTS

Yang You (Supervisor: **Laetitia Michou**) completed a summer studentship at the Laval Centre. Her project was *“Clinical validity and clinical utility of a screening test for Paget's disease of bone”*.

Ria Garg (Supervisor: **Mary De Vera**) is a 3rd year PharmD student at UBC's Faculty of Pharmaceutical Sciences. Her project title is *“Roles and perspectives of partners of women with rheumatoid arthritis on reproductive decision making: a Constructivist Grounded Theory study”*.

TRAINEE SALARY AWARDS & SCIENTIFIC AWARDS

Arthritis Research Canada Calgary Trainee **Darren Mazzei** (Supervisor: **Deborah Marshall**) was awarded a three-year Arthritis Society doctoral salary award of \$63,000. His project is *‘Informing public funding decisions for an exercise and education program for osteoarthritis’*.

Christina Le (supervisor, **Jackie Whittaker**) has been awarded an Arthritis Society two-year doctoral salary award worth a total of \$42,000 (\$21,000 from the Society and \$21,000 from funding already in place for Dr. Whittaker). Her project is *‘Health-related quality of life following a youth sport-related knee injury: Implications for preventing post-traumatic osteoarthritis and promoting lifelong well-being’*.

Kelsey Chomistek (Supervisors: **Cheryl Barnabe** & Heinrike Schmeling) was awarded the Arthritis Alliance of Canada Master's Student Research Award.

Three Arthritis Research Canada Trainees were awarded competitive Arthritis Research Canada/Lilly Early Rheumatology Researcher Travel Scholarships to attend the 2019 National Meetings of the American College of Rheumatology in Atlanta. **May Choi** (Supervisors: **Deborah Marshall** & Marv Fritzler) was first author on one abstract and co-author on 2 others. (#12, 46 & 82 below); **Gloria Li** (Supervisor: **Antonio Aviña**) presented four papers as first author, with three of them as oral podium presentations (#39 - #42 below); and **Teresa Szlachetka** (Supervisor: **Diane Lacaille**) presented a paper for the first time at this meeting. (#65 below).

Luiza Grazziotin Lago (Supervisor: **Deborah Marshall**) has been awarded a three year \$30,000/year Alberta Innovates Graduate Studentship in Health Innovation for her project *“Cost-effectiveness of early initiation of personalized biologic treatment in children with juvenile idiopathic arthritis”*.

André Luquini (Supervisor: **Diane Lacaille**) has been awarded a University of British Columbia Faculty of Medicine Graduate award of \$3,000 for his PhD *“evaluating at-work productivity in people with inflammatory arthritis”*.

Jasmin Ma (Supervisor: **Linda Li**) received a trio of awards for her project titled *“Improving strength training in people with rheumatoid arthritis: A foundational behaviour change science approach”*: 1) a 3-year \$151,500 Canadian Institutes of Health Research Post-doctoral Fellowship Award for her project 2) The Arthritis Society postdoctoral Fellowship (\$60,000 plus \$60K from other sources over 3 years), and 3) a Michael Smith Foundation for Health Research postdoctoral award of \$124,000 over 3 years.

Gloria Li (Supervisors: **Antonio Aviña-Zubieta** & Mahyar Etminan) has been awarded a 3-year \$105,000 Canadian Institutes of Health Research Doctoral Award for her project titled *“The risk of multiple sclerosis among users of tumor necrosis factor inhibitors: A Canadian population-based study”*.

Linda Truong (Supervisor: **Jackie Whittaker**) was awarded the UBC 4-Year Fellowship Award (\$72,000/year x 4 years, plus free tuition). Her thesis project title is *“The role of psychological, social, and contextual factors in recovery and return to sport after a sport-related knee injury”*.

Lawrence Mainville (Supervisor: **Paul Fortin**) has received three awards: 1) A Canadian Institutes of Health Research Canada graduate scholarship-Master's grant (\$17,500), project title *“Public versus Private Drug Insurance and Degree of Severity of Psoriasis in Patients with Prescribed Biologics”*; 2) A scholarship from the Professor's Support Fund for Academic Activities, Department of Medicine, Université Laval (\$8,000); 3) a Clinical Research Scholarship from the Sustainable Health Scholarship Fund, Faculty of Medicine, Université Laval (\$2,000).

HONOURS

Christina Le (Supervisor: **Jackie Whittaker**) was honoured for the “Top Oral Presentation in Population and Community Health” for her abstract *“Understanding quality of life after a youth sport-related knee injury”* at the Canadian Bone and Joint Conference, Virtual (Zoom®), June 13, 2020.

Andre Luquini's abstract (Supervisor: **Diane Lacaille**) on the effectiveness of the Making it Work™ program at improving at-work productivity and preventing work cessation was selected for the opening plenary presentation at EULAR, the European scientific meeting for rheumatology in June, as well as for a plenary presentation at the Canadian Rheumatology Association annual scientific meeting in February.

Faculty

HONOURS

On September 19, 2019 **Linda Li** was inducted as a Fellow of the Canadian Academy of Health Sciences in recognition of her significant contribution to health sciences. The Academy requires that one has consistently demonstrated the highest level of leadership, creativity, research skill and research productivity. Dr. Li has been a leader in advancing the engagement of the public in research from the idea stage to the promotion of the final results, as well as a leader in studying digital methods for disseminating results and a superstar in knowledge translation.

At the September 2019 Board of Directors meeting **Ines Colmegna** was unanimously voted to become a new Arthritis Research Canada/Arthrite-recherche Canada scientist. Dr. Colmegna's research focuses on defining basic mechanisms accounting for the disruption of immune tolerance in patients with rheumatoid arthritis.

Jackie Whittaker was awarded the Arthritis Alliance of Canada Early Career Researcher in Basic and Clinical Sciences and **Glen Hazlewood** was awarded the Early Career Researcher in Health Science/Population Health.

John Esdaile has been awarded a Canadian Rheumatology Association Master Award – a recognition for CRA members aged 65 and older who have made outstanding contributions to the field of rheumatology and excelled in one or more of the following ways: outstanding service to patients, outstanding administrative service, excellence in rheumatology teaching and education, and/or excellence in rheumatology research.

Claire Barber was awarded the Canadian Rheumatology Association 2020 Emerging Investigator award. She is the Canadian authority and a well-recognized international leader for quality assessment in arthritis. Dr. Barber is measuring quality of care, and even more importantly determining how to improve it.

Paul Fortin was awarded the Canadian Rheumatology Association 2020 Distinguished Investigator award. This award goes to a Senior Scientist who has established his or her name internationally for outstanding science. Dr. Fortin is a superstar in patient focused research to advance care and improve well-being of people living with systemic lupus erythematosus.

Cheryl Barnabe was named one of the top 5% of Reviewers for the Arthritis Care & Research Journal for 2019.

Jackie Whittaker was invited to lead the Osteoarthritis Year in Review for Rehabilitation presentation at the World Congress on Osteoarthritis meeting in Vienna.

FACULTY SALARY AWARDS & SCIENTIFIC AWARDS

SALARY AWARDS

Jackie Whittaker and Claire Barber are both recipients of The Arthritis Society Stars Career Salary award. **Jackie Whittaker** was awarded \$375,000 over three years for her project *“Overcoming obstacles to prevent osteoarthritis after a sport-related injury”*. **Claire Barber** was also awarded \$375,000 over three years for her project *“A Better Match: Transforming rheumatoid arthritis care through tailored follow-up strategies based on disease activity and patient complexity, a pragmatic randomized controlled trial”*.

Jackie Whittaker has been awarded a prestigious five-year salary award in the amount of \$450,000, the Michael Smith Foundation for Health Research Scholar Award for her research program aimed at preventing osteoarthritis after sports related injury in youth.

SCIENTIFIC AWARDS

Laëtitia Michou has been awarded a one year Arthritis Centre grant of \$14,995 from The Arthritis Society. The project title is *“Familial aggregation between rheumatoid arthritis, systemic lupus and autoimmune diseases”*. The purpose of this project is to obtain, by means of a telephone interview, an estimate of the prevalence of autoimmune diseases among first- and second-degree relatives of patients with rheumatoid arthritis or systemic lupus erythematosus.

Linda Li is a Co-Investigator on two implementation team grants from the Michael Smith Foundation for Health Research. Both grants are for \$500,000 each over three years. Co-Primary Investigators on the first one include Teresa Liu Ambrose, Megan Oakley, Fabio Feldman, Jennifer Davis and Co-Investigators **Hui Xie, Jasmin Ma, Cheryl Koehn, Chris Shaw** and Deborah Jehu. The title is *“Implementing an evidence-based exercise program to reduce falls in community-dwelling older adults”*.

Primary Investigators on the second award are Sonia Singh, Larry Funnel, and Tania Bubela. **Linda Li** leads the implementation component. The title is *“Breaking the cycle of recurrent fracture: Scaling up a secondary fracture prevention program in Fraser Health to inform spread across BC”*.

Paul Fortin is Co-principal investigator with Eric Boilard on two grants, a three year \$360,000 grant from the arthritis society and a five year \$910,000 grant from CIHR, for their project *“platelet and neutrophils the two culprits mediating pain”*.

He is also Coinvestigator with PI Fawzi Aoudjit on another \$360,000 three year grant from the arthritis society on *“The role of discoidin domain receptor 1 in T cell migration and arthritis”*.

Paul Fortin is a Co-Investigator on a five-year \$910,000 Canadian Institutes of Health Research Project Grant titled *“Platelets and neutrophils: The two culprits mediating pain in inflammatory arthritis”*. The Principal Investigator on this award is Eric Boilard.

Paul Fortin is a collaborator on a 3-year \$180,000 grant from the Kidney Foundation of Canada titled *“Impact of the autoimmune anti-LG3 response on lupus nephritis”*. The Principal Investigator is Mélanie Dieudé.

Claire Barber has been awarded \$299,500 over three years as the Principal Applicant on a Canadian Institutes of Health Research grant titled *“Understanding the effect of adherence to system-level performance measures on outcomes for rheumatoid arthritis”*. Co-Principal Investigators are **Diane Lacaille** and Jessica Widdifield. Co-Investigators include **Antonio Aviña, John Esdaile, Cheryl Barnabe, Glen Hazlewood, Deborah Marshall, Hui Xie,** Dianne Mosher and others.

Claire Barber has been awarded a \$275.00 Patient Engagement platform Accelerator Award from the Alberta SPOR Support Unit for her project titled *“Patient Advisory Council for Optimizing Rheumatoid Arthritis Care”*. The aim is to have patients with lived-experience of RA inform and advise the initiatives related to their care. The goal is for the Council to help represent perspectives and needs of RA patients receiving care in Calgary-based clinics.

Catherine Backman is one of several Principal Investigators on an ongoing CIHR project which was awarded an additional five years of funding totaling \$1,996,990. The project title is *“Canadian Musculoskeletal (MSK) Rehab Research Network”*. Other PI's are Joy MacDermid, Trevor Birmingham, Laurent Bouyer, **Deborah Marshall,** Rebecca Moyer, Janet Ronsky, Jean-Sebastien Roy, and Alik Thomas. **Jackie Whittaker** and **Michael Hunt** are among 100 co-applicants and collaborators on this project.

Diane Lacaille is a Co-Investigator on a \$321,300 over 2.5 years Canadian Institutes of Health Research grant titled *“Accelerating discoveries: The employment trajectory of young adults with systemic lupus erythematosus”*. The Principal Investigator is Lily Lim.

Alison Hoens is a collaborator on a 5-year \$604,350 Canadian Institutes of Health Research Project Grant titled *“Improving pain education across entry-level physiotherapy programs in Canada: An integrated knowledge translation study”*. Timothy Wideman and Geoffrey Bostick are two of several Principal Investigators on the project which also includes a large roster of Co-Investigators.

Cheryl Barnabe is a Co-Principal Investigator on a \$3.5 million Canadian Institutes of Health Research grant to create a network to address health inequities in Indigenous populations, entitled *“Indigenous Primary Health Care and Policy Research Network in Alberta”*. There are nine Co-Principal Investigators including Lynden Crowshoe and Cara Bablitz.

Paul Fortin is the Principal Investigator on a three-year \$300,000 grant from The Arthritis Society titled *“The impact of antimalarial drugs in arthritis patients exposed to SARS-CoV-2 - the CoVIRAL project”*. Eric Boilard and **Deborah Da Costa** are Co-Principal Investigators.

Antonio Aviña is Principal Investigator with Co-investigators **Diane Lacaille, Jacek Kopec, Hui Xie**, Johnathan Loree and **Alison Hoens** on a COVID-19 rapid response grant from the Michael Smith Foundation for Health Research. This 14 month \$150,000 project will evaluate *“Risk and outcome of COVID-19 in patients exposed to immunosuppressive and immunomodulatory agents in British Columbia. A population-based study.”*

Linda Li is a Co-Principal Investigator on a one year \$100,000 Canadian Institutes of Health Research grant titled *“Strengthening and validation of a new 360-degree tool to evaluate patient and public engagement in health research”*. Other Principal Investigators include Ahmed Mohamed Abou-Setta and Andrea Tricco.

Jackie Whittaker is Co-Principal Investigator with APAB member **Trish Silvester-Lee** on a one year \$20,000 award from the BC Support Unit and the Michael Smith Foundation for Health Research. The project title is *“Feasibility and Acceptability of the Stop OsteoARthritis (SOAR) Program”*. Co-Investigators include **Linda Li, Hui Xie, Michael Hunt, Alison Hoens, Linda Truong**, Ewa Roos and others.

Jackie Whittaker is also the Principal Investigator on a \$10,000, 2020 Canadian MSK Rehab Network Pilot Grant for the project *“Feasibility of the TeleRehab Stop OsteoARthritis (SOAR) Program”*. Co-Investigators include APAB member **Trish Silvester-Lee, Linda Li, Michael Hunt, Linda Truong**, Amber Mosewich, Maxi Miciak, Andrea Pajcik, and Christina Le

Diane Lacaille is the Principal Investigator with Co-Investigators **Antonio Aviña, Hui Xie, John Esdaile**, and collaborators **Cheryl Koehn**, Tijana Fazlagic (from the BC Ministry of Health), and Jason Gordon, Stephanie Ensworth, Cathy Flanagan, and Alison Kydd (from BC pharmacare) on a grant funded by the Canadian Rheumatology Association (CIORA) for \$114,000 over 2 years that will evaluate the biosimilar transition policy recently implemented in BC. It is titled *“Safety and effectiveness of biosimilar anti-TNF agents in BC – Exploiting a natural experiment from a change in health policy”*.

Nick Bansback is the Principal Investigator on a grant of \$98,000 over 2 years from the Canadian Rheumatology Association (CIORA) titled *“Health economic evaluation of the mandatory switching policy for biosimilars in patients with rheumatoid arthritis”*. Co-investigators are **Mark Harrison, Aslam Anis**, Jason Kur, Michael Law, and **Mary De Vera**.

Shahin Jamal is the arthritis lead and Co-investigator on a grant (Principal Investigators Janet Roberts, Carrie Ye) for \$74,000 over 2 years from the Canadian Rheumatology Association (CIORA) to study a new group of cancer drugs called check-point inhibitors which are on average life-prolonging/saving but can cause serious arthritis as a side-effect. The grant title is *“Improving the care of cancer patients receiving immunotherapy who develop rheumatic immune-related complications, and those with pre-existing rheumatic disease, through online education with health care providers: An Initiative of CanRIO (Canadian Research Group of Rheumatology in Immuno-Oncology)”*.

Paul Fortin and **Antonio Aviña** are Co-Investigators on a \$117,098 Canadian Initiative for Outcomes in Rheumatology (CIORA) grant titled *“Work disability and function in systematic lupus erythematosus: a national mixed-methods sequential explanatory study”*. The Principal Investigators are Behdin Nowrouzi-Kia and Zahi Touma. Other Co-Investigators include Sasha Bernatsky, Evelyn Vinet, Christian Pineault and others.

Ann Clarke and her Trainee **Megan Barber** are Co-Investigators on a \$35,000 Lupus Canada Competition Catalyst Grant. The project title is *“Antiphospholipid is associated with a high burden of obstetrical complications”* and the Principal Investigator is Leslie Skeith.

Signed:



Diane Lacaille, MD, MHSc, FRCPC
Mary Pack Chair in Rheumatology Research,
Scientific Director, Arthritis Research Canada
Professor of Medicine, University of British Columbia

Appendix I

FUNDING FROM JULY 1, 2019 TO JUNE 30, 2020

AIHS - Alberta Innovates Health Solutions; CAN - Canadian Arthritis Network; CIORA - Canadian Initiative for Outcomes in Rheumatoid Arthritis; CIHR - Canadian Institutes of Health Research; CRA - Canadian Rheumatology Association; CHHM - Centre for Hip Health and Mobility; HSFC - Heart and Stroke Foundation of Canada; EULAR - European League Against Rheumatism; MSFHR - Michael Smith Foundation for Health Research; NCI - National Cancer Institute; NIH - National Institutes of Health; NCE - Networks of Centres of Excellence; TAS - The Arthritis Society;; UBC - University of British Columbia; SPARTAN - Spondyloarthritis research and treatment network; SRCC - Spondyloarthritis Research Consortium of Canada

SCIENTIST FUNDING - Operating Grants							
Funding Agency	Title	PI(s)	Co-I(s)	Annual Amount	Total Awarded	Start Date	End Date
CIHR	Canadian network for advanced interdisciplinary methods for prospective studies of drug safety and effectiveness	Abrahamowicz M	D Lacaille , A Berard, S Bernatsky, C Hohl, L Levesque, A Levy, Y Moride, L Pilote, L Bessette, L Blais, G Boire, C Bombardier, D Buckeridge, S Cadarette, R Capek, P Fortin et al	\$250,000	\$1,250,000	Sep-14	Aug-19
CIHR	New statistical methods for cohort studies of adverse effects of medications	Abrahamowicz M	Bernatsky S, Blais L, Brophy J, Buckeridge D, Bérard A, Capek R, De Vera M , Dixon W, Durand M, Fortin P , Klein M, Lacaille D , Moodie E, Moura C, Pilote L	\$55,724.60	\$278,623	Jul-16	Jun-21
CIHR	The pricing of generic drugs and its impact on market structure, competitiveness and security of supply	Anis A	P Grootendorst, A Hollis, C Ingram, L Lynd, W Zhang	\$80,325	\$240,975	Apr-17	Mar-20
CIHR/SPOR Support Units/BC SUPPORT	Support for People and Patient-Oriented Research and Trials (SUPPORT) - CHEOS	Anis A		\$329,384	\$1,646,920	Nov-16	Oct-21

CIHR	Risk of Retinal Toxicity in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis on Long-term Hydroxychloroquine Therapy	Avina-Zubieta A	H Choi, M Dawes, M Etminan, D Lacaille, LC Li, D Maberley, K Shojanian, H Xie	\$141,525	\$707,625	Mar-19	Feb-24
CIHR	Towards improving screening of retinal toxicity of hydroxychloroquine in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)	Avina-Zubieta A	Esdaile JM, Lacaille D, Shojanian K	\$10,000	\$10,000	May-19	Apr-20
Michael Smith Foundation for Health Research	Risk and outcome of COVID-19 in patients exposed to immunosuppressive and immunomodulatory agents (IIA) in British Columbia. A population-based study.	Avina-Zubieta A	D Lacaille, H Xie, J Kopec, Jonathan Loree	\$149,898	\$149,898	Apr-20	Mar-21
BC SUPPORT Unit COVID-19 Partner Engagement Funding	Risk and outcome of COVID-19 in patients exposed to immunosuppressive and immunomodulatory agents (IIA) in British Columbia. A population-based study - Partner Engagement Activities	Avina-Zubieta A	D Lacaille, H Xie, J Kopec, Jonathan Loree	\$6,750	\$6,750	Apr-20	Mar-21
CIHR	Tumor necrosis factor inhibitors (TNFi) and Risk of Multiple Sclerosis	Etminan M, Avina-Zubieta JA	D Lacaille, H Tremlett, L Targownik, RA Marrie, GG Kaplan, JN Pena-Sanchez, H Xie	\$62,333.33	\$187,000	Sep-19	Aug-22

CIHR	Canadian Musculoskeletal (MSK) Rehab Research Network	MacDermid J, Backman C , Birmingham T, Bouer L, Marshall D, Moyer R, Ronsky J, Roy JS, Thomas A	Knowledge User: K Hofstetter, M Hunt , J Whittaker	\$399,398	\$1,996,990	Jan-20	Dec-24
CIORA	Health Economic Evaluation of the Mandatory Switching Policy for Biosimilars in Patients with Rheumatoid Arthritis	Bansback N		\$49,000	\$98,000	Jul-20	Jun-22
CIHR	Improving access to medicines in Canada and abroad	Law M	N Bansback , L Goldsmith, M Harrison , AM Holbrook, S Majumdar, M Mamdani, S Wong	\$89,214	\$624,498	Jul-16	Jun-23
CIHR	Design for better health: user-centred design and evaluation of interactive media for health education, communication and decision-making	Witteman H	J Ancker, P Archambault, N Bansback , MD Beaulieu, J Bender, J Bettinger, C Chambers, D Chan, H Colquhoun, S Desroches, et al	\$8,510	\$544,538	Jul-16	Jun-21
CIHR	Development of a patient-centered balanced scorecard approach to improve quality of care in rheumatoid arthritis patients in Canada	Barber C, Lacaille D	C Barnabe , G Hazlewood , J Homik, L Li , P MacMullan, DA Marshall , D Mosher, J Rankin, K Then, K English , K Tsui	\$91,800	\$183,600	Apr 17	Mar 19
CIORA	Optimizing early treatment strategies in early RA through shared decision-making	Barber C, Hazlewood G	Bansback N , Li LC , Mosher D, Proulx L, Richards D	\$59,850	\$119,700	Jul-19	Jun-21

CIHR	Understanding the effect of adherence to system-level performance measures on outcomes for rheumatoid arthritis	Barber C (NPI), Lacaille D (PI), Widdifield J (PI)	Abrahamowicz M, Avina-Zubieta JA, Barnabe C, Esdaile JM, Faris P, Hazlewood G, Katz S, MacMullan P, Marshall DA, Mosher D, Xie H	\$76,500	\$229,500	Apr-20	Mar-23
CIHR	Arthritis Care for Indigenous Populations'	Barnabe C	D Marshall, S Bernatsky, L Lis, W Maksymowych, V Bykerk, G Hazlewood, J Jull, L Crowshoe et al	\$115,000	\$575,000	Jul-15	Jun-20
CIHR	Alberta Indigenous Mentorship in Health Innovation Network (AIM-HI Network)	Barnabe C, Healy B, Tailfeathers E, Crowshoe L, Currie C, Fellner k, Henry R, Voyageur C	R Weasel Fat, J Baker, B Bastien, S Chisan, A Greenshaw, R Henderson, A Kennedy, S Kutz, A Loyola-Sanchez, L ManyGuns, T Oosterbroek, M Rock, W Shotyk	\$200,000	\$1,000,000	Apr-17	Mar-22
CIORA	An initiative to address Indigenous patient and community educational needs in rheumatic diseases	Barnabe C, Loyola-Sanchez A	T Bear Chief, V Bear Chief, C Brough, S Calf Robe, L Crane, L Crowshoe, R Greenslade, R Henderson, T Linkert, B Little Chief, H Melting Tallow, S Samanani, T Scalplock, C Sorensen, T White	\$57,500	\$115,000	Jul-18	Jun-20
CIHR	IDEATE (InDigEnous heAlTh Equity) Network for primary health care and policy research in Alberta	Barnabe C, Bablitz C, Crowshoe L, Green M, Henderson R, Leduc C, Montesanti S, Murry A, Tailfeathers E	J Auger, W Austen, L Bastien, N Cardinal, H Crowshoe, S Funnell, L Green, B Healy, R Henry, M Landrie, J Leason, R Littlechild, N McRee, M Potestio, S Samanani, C Sarin, E Toth, M White	\$75,000	\$75,000	Oct-18	Sep-19

CIHR	Indigenous Primary Health Care and Policy Research (IPH CPR) Network in Alberta	Barnabe C , Crowshoe L, Bablitz C, Green M, Henderson R, Kennedy A, Montesanti S, Murry A, Roach P, Tailfeathers E	Auger C, Auger J, Baker J, Chowdhury C, Crowshoe T et al	\$700,000	\$3,500,000	Oct-19	Sep-24
CIHR	UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease	Benseler S , Swart J, Wulffraat N, Yeung R	Bombardier C, Cafazzo J, Eijkelkamp N, Goldenberg A, Guzman J, Ijzerman M, Marshall DA et al	\$204,750.60	\$1,023,753	Feb-17	Jan-22
The Arthritis Society	Establishing the validity of quality of life measures in young children with juvenile idiopathic arthritis	Benseler S , Currie G	D Marshall , M Twilt, A Ohinmaa, Understanding Childhood with Arthritis Network Canada - Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease	\$108,000.00	\$324,000	Oct-18	Sep-21
CIHR	Development and validation of a new method for measuring cartilage load using upright open Magnetic Resonance Imaging (MRI)	Wilson D	J Cibere	\$118,500	\$474,000	Jul-16	Jun-20
CIHR	Population-based longitudinal cohort study of femoroacetabular impingement of the hip using magnetic resonance imaging outcomes	Cibere J	J Esdaile , B Forster, J Kopec , L Li , D Wilson, H Wong,	\$177,225	\$531,674	Oct-18	Sep-21
Alliance for Lupus Research	Calgary Site PI & Lupus Clinical Investigators Network (LuCIN)	Clarke AE , Barr S		\$80,000	\$160,000	Aug-16	open ended

CIHR	Evidence to action for Canadian and global mobile health (mHealth) communication to promote patient engagement in care: a rigorous implementation science approach	Lester R	V Cook, M De Vera , J Fitzgerald, N Ford, J Johnston, A Kazi, M Murray, L Mwai, A Patel, M Schechter, S Skinner, P Spittal, M VanDerKop	\$80,593	\$402,966	Jul-15	Jun-20
The Arthritis Society	Mapping the epidemiology and the role of treatments in mental health complications in inflammatory arthritis	De Vera M	D Da Costa , J Puyat, J Esdaille , K Shojania , A Avina-Zubieta , A Howren ,	\$70,000	\$210,000	Oct-18	Sep-22
CIORA	Making medication decisions for family planning and pregnancy among women with rheumatoid arthritis (MOTHERS)	De Vera M	N Rebic , N Amiri, C Baldwin, S Ensworth, G Hazlewood , L Proulx	\$58,238	\$58,238	Jul-19	Jun-20
CIHR	PRECISION: Preventing Complications from Inflammatory Skin, Joint and Bowel Conditions	Esdaille J	C Goldsmith , M De Vera , J Dutz , D Lacaille , LC Li	\$484,538	\$2,422,690	Jul-14	Jun-22
CIHR - Foundation Scheme	Platelets and their microparticles: versatile players of inflammation	Boilard, E	P Fortin	\$286,979	\$1,434,894	Sep-14	Aug-19
CIHR- Operating Grant	Role of autotoxin bound to platelet-derived microparticles to development of vascular damage in	Bourgoin S	E Boilard, P Fortin	\$157,781	\$788,904	Mar-15	Feb-20
CIHR	Impact of internet delivered cognitive behavioral therapy for insomnia in persons with systemic lupus erythematosus: a randomized clinical trial	Fortin P , Da Costa D , Savard J	E Rahme	\$100,000	\$100,000	Mar-19	Feb-20

CIHR	Mapping anti-mitochondrial antibodies in systemic lupus erythematosus	Fortin P	M Abrahamowicz , E Boilard, J Rauch	\$138,760	\$416,280	Apr-19	Mar-22
The Arthritis Society	The impact of antimalarial drugs in arthritis patients exposed to SARS-CoV-2 - the CoVIRAL project	Fortin P	E Boilard, D Da Costa	\$150,000	\$300,000	Jul-20	Jun-22
CIORA	Perspectives on the implementation of a multidisciplinary conference fee code for community-based patients with rheumatic disease in BC (RHEUM-NURSE)	Harrison M	M Teo, S Munro, M De Vera , J Kur, C Koehn, P Patrick, K Shojania , M Aguiar	\$66,655	\$66,655	Jul-19	Jun-20
CIHR	A pragmatic registry-based randomized trial of drug tapering in rheumatoid arthritis	Hazlewood G , Bykerk V	N Bansback , R Deardon, L Proulx, G Tomlinson, C Barber , E Keystone, D Richards, P Tugwell, S Bartlett , D Marshall , O Schier, G Boire, J Pope, C Thorne	\$159,694	\$638,776	Apr-18	Mar-21
CIHR	Hydroxychloroquine in systemic lupus	Hazlewood G , Bernatsky S	Abrahamowicz M , Bartlett S , Clarke A , Fortin P , Hanly J, Li LC, Peschken C, Vinet E	\$68,468	\$342,340	Apr-18	Mar-23
CIORA	Bringing patients and therapies together sooner: building clinical trial capacity in myositis to facilitate early access to treatments and improved outcomes	Hudson M	Avina-Zubieta A , Fortin P	\$60,000	\$120,000	Oct-17	Sep-19
CIHR	Phase I/II randomized controlled clinical trial of umbilical cord-derived mesenchymal stromal cells in refractory systemic sclerosis	Hudson M , Colmegna I , Farge D	Hoa SA, Laneuville P, Peltier L, Resche-Rigon M, Schnitzer M	\$140,000	\$420,000	Oct-19	Mar-22

CIHR	Canadian MSK Rehab Research Network	Astephen Wilson JL, Birmingham T, Lyddiatt A, Macdermid J, Robinovitch S, Roy JS	M Ashe, D Beaton, L Beaupre, M Begon, L Bouyer, L Carlesso, M Choiniere, J Cote, N Dahan-Oliel, K Deluzio, F Desmeules, C Dionne, CA Emery, F Feldman, MA Hunt, DA Marshall et al	\$14,205	\$366,667	Sep-16	Aug-19
CIHR	Linking biomechanical and imaging outcomes to better understand the effects of running on knee joint health	Hunt MA	JF Esculier , A Rauscher, J Taunton, D Wilson	\$135,405	\$677,025	Apr-19	Mar-24
CIHR	Development of a new life expectancy and quality of life prediction model	Kopec J	J Esdaile, LC Li, L Feehan, H Xie	\$100,000	\$200,000	Oct-17	Sep-19
CIHR	Development and validation of Canadian health literacy measurement tool for chronic disease management.	Fitzgerald M, Kopec JA	I Rootman, SD Aaron, C Bergeron, LP Boulet, J Bourbeau, R Goldstein, S Gupta et al	\$160,601	\$803,004	Jul-15	Jun-20
The Arthritis Society	Proof of concept study of an EMR reminder intervention to optimize the primary and secondary prevention of comorbidities in people with inflammatory arthritis	Lacaille D	O Tseng, C Barber, L Li, H Xie, JA Aviña-Zubieta, J Esdaile	\$120,000	\$360,000	Sep-19	Aug-19
CIORA	Safety and effectiveness of biosimilar anti-TNF agents in British Columbia – Exploiting a natural experiment from a change in health policy	Lacaille D	JA Avina-Zubieta, H Xie, J Esdaile Collaborators: C Koehn, T Fazlagic, J Gordon, S Ensworth, C Flanagan, A Kydd	\$57,000	\$114,000	Jul-20	Jun-22

The Arthritis Society	Empowering active self-management of arthritis: Raising the bar with OPERAS (an On-demand Program to Empower Active Self-management)	Li LC	T Liu-Ambrose, C Backman , C Shaw, J Esdaile , K Miller, R Petrella, L Feehan , C Koehn , C Goldsmith , P Adam	\$120,000	\$360,000	Oct-16	Sep-19
CIHR	An app-based intervention to empower self-management for people with rheumatoid arthritis	Li LC, Lacaille D	C Backman, JM Esdaile, LM Feehan, H Xie , K Miller, C Shaw Patient Partners: C Koehn, K English Collaborator: P Adam Tech Partner: Tactica Interactive	\$100,000	\$200,000	Sep-17	Aug-19
CIHR	SPOR Evidence Alliance	Tricco A, Straus S, Abou-Setta AM, Barker K, Clement F, Clifford TJ, Colquhoun H, Curran J, Godfrey C, Isaranuwachai W, LeBlanc A, Li LC , Moffitt P, Moher D, Teare GF	Barnabe C , Graham I, Ivers N, Klassen T, Legare F, Mitton C, Morin S, Scott S, Sibely K, Snelgrove-Clarke E, Squires J, plus > 100 investigators	\$999,378	\$4,996,890	Jul-17	Jun-22
CIORA	Power to the Patients: Reshaping Knee Osteoarthritis Diagnosis and Secondary Prevention with E-Health	Li LC, Esdaile J	J Cibere , G Hawker, H Xie, C Koehn , A Fajardo	\$57,500	\$115,000	Jul-18	Jun-20
BC SUPPORT Unit, BC Academic Health Science Network (AHSN)	Integrated KT 2.0: Development of an Online Citizen Science Portal	Li LC , Currie L, Michalak E	D Gramala, C Shaw, Patient Partners: C Koehn, D Cooper, S Loo	\$112,350	\$224,700	Apr-18	Mar-20

MSFHR	Implementing an evidence-based exercise program to reduce falls in community-dwelling seniors	Li LC	T Liu-Ambrose, S Murphy, F Feldman, M Oakey, J Davis, J Ma , C Koehn, L Dian, D Jehu, H Xie	\$166,667	\$500,000	Jun-19	May-22
CIHR	Strengthening and validation of a new 360-degree tool to evaluate patient and public engagement in health research	Jeyaraman, M, Shimmin, CA, Abou-Setta, AM, Charatte, CJ, Klassen TP, Li, LC , Moore, A, Tricco, AC	T Beaudry, SE Straus, JM Edwards, T Rabbani, KM Sibley, RL Woodgate	\$100,000	\$100,000	Apr-20	Mar-21
CIHR	Medically at-risk drivers: The road to developing evidence-based fitness to drive guidelines	Crizzle A, Elzohairy Y, Vrkljan B	J Dow, G Equakun, LC Li , S Marshall, N Meger E Mychael et al	\$133,875	\$803,250	Apr-18	Mar-24
CIHR	Transforming the practices of KT: Embedding Gender	Straus S, Moore J	A Chambers, L Giangregorio, A Giguere, I Graham, J Hamid, J Holroyd Leduc, C Kelly, LC Li , J Presseau, P Rochom et al	\$150,000	\$450,000	May-17	Mar-20
Arthritis Alliance of Canada - Legacy Award	Biosimilar starts and switches, what we can learn from patients?	Marshall DA	TBA	\$35,000	\$35,000	Jan-20	Jun-21

SkinPact Excellence in Education - Expert Panel Award	Dermatology Rheumatology Educational Tool for Autoimmune Manifestations, the DREAM TOOL	Shojania K, Dutz J , Keeling S, Au S, O'Brien E, Fahim S, Gniadecki R, Green P, Keeling C, Lima H, Mydlarski R, Barber K, Brassard K, Netchiporouk E, Pinard J, Hudson M		\$12,809	\$12,809	Apr-19	Mar-20
BC SUPPORT UNIT/Michael Smith Foundation for Health Research 2020 Pathway to Patient-Orientated Research (P2P) Award	Feasibility and Acceptability of the Stop OsteoArthritis (SOAR) Program	Whittaker J	Silvester-Lee T (Patient Co-Lead), Xie H, Hoens A, Hunt M , Roos E, Mosewich A, Miciak M, Pajkic A (Patient partner, Alberta)	\$20,000	\$20,000	Apr-20	Mar-21
MSK Rehab Network	Feasibility of the TeleRehab Stop OsteoArthritis (SOAR) Program	Whittaker J	Silvester-Lee T (Patient Co-Lead), Hunt M , Mosewich A, Miciak M, Le C, Pajkic A (Patient partner, Alberta)	\$10,000	\$10,000	Jun-20	May-21

Natural Sciences & Engineering Research Council (NSERC)	Statistical Methods for bias controlling in the analysis of rich data	Xie, H		\$15,000	\$75,000	Apr-18	Mar-23
---	---	---------------	--	----------	----------	--------	--------

SCIENTIST FUNDING - Salary Grants

Peer Review

Funding Agency	Title	Faculty	Start/End Date	Annual Amount	Total Awarded
CIHR	Canada Research Chair in Rheumatoid Arthritis and Autoimmune Diseases (Tier 2)	Barnabe C	Oct 19 - Sep 24	\$100,000	\$500,000
CIHR	Canada Research Chair in Medication Adherence, Utilization, and Outcomes (Scientist)	De Vera M	Apr 17 - Mar 22	\$100,000	\$500,000
CIHR	Canada Research Chair in Systematic Autoimmune Rheumatic Diseases (Tier I) - Renewal	P Fortin	Apr19 - Mar 26	\$200,000	\$1,400,000
MSFHR	Scholar Award - Incentivizing the delivery of sustainable care of chronic diseases in Canada: case studies in musculoskeletal disease	Harrison M	Jul 17 - Jun 22	\$90,000	\$450,000
CIHR	New Investigator Salary Award - Bridging the gap between research evidence and patient-centered treatment approaches for chronic immune-mediated diseases	Hazlewood G	Jul 16 - Jun 21	\$60,000	\$300,000

TAS	New Investigator Salary Award - Impacts of integrating the patients' voice into the process of treatment selection for rheumatoid arthritis	Hazlewood G	Aug 16 - Jul 19	\$60,000	\$180,000
Canadian Rheumatology Association	Emerging Investigator Award	Hazlewood G	Feb-19	\$2,500	\$2,500
MSFHR	Career Clinical Scholar	Hunt M	Jul-12 - Jul-20	\$79,375	\$635,000
Canada Research Chair Program	Canada Research Chair in Patient-Oriented Knowledge Translation	Li L	Apr-19 - Mar 24	\$100,000	\$500,000
Government of Canada	Canada Research Chair in Systemic Autoimmune Rheumatic Diseases	Fortin P	Apr-12 - Jun-26	\$200,000	\$2,750,000
UofC	Arthur J.E. Child Chair in Rheumatology Outcomes Research	Marshall D	Jul-12 - Jun-17		

Non Peer Review

BC Lupus Society	Scholar Award	Avina A	Jul-10 - Jun-19	\$50,000	\$350,000
UBC	Mary Pack Chair	Lacaille D	Sep-11 -	\$164,759	\$823,799
UBC	Harold Robinson-Arthritis Society Chair in Rehabilitation Sciences	Li L	Jul-11 -	\$94,333	\$283,000
SFU	Maureen and Milan Illich Chair in Statistics and Information Sciences for Arthritis and Musculoskeletal Disease	Xie H	Sep-15 - Aug-20	\$172,000	\$4,000,000

TRAINEE AWARDS

Funding Agency	Title	Trainee	Supervisor	Start/End Date	Annual Amount	Total Awarded
CIHR	Health System Impact Fellowship - Patient/Public Engagement Measurement and Evaluation Project (PEMEP) within the British Columbia Ministry of Health's Patients as Partners Initiative	Hamilton C	L Li	Sep 18 - Aug 20	\$77,500	\$155,000
CIHR	CIHR Postdoctoral Award - Safety and Effectiveness of Anti-diabetic Drugs in Pregestational Diabetes	Tsao N	M De Vera	Sep 18 - Aug 21	\$60,000	\$180,000
CIHR - TAS	Building a foundation for an economic business case for models of care for patients with Inflammatory Arthritis in Canada (Supervisors: D Marshall, D Mosher)	Lopatina E	Marshall D	Sep 18 - Aug 19	\$35,000	\$35,000
CIHR	CIHR Postdoctoral Award - Safety and Effectiveness of Anti-diabetic Drugs in Pregestational Diabetes	Tsao N	M De Vera	Sep 18 - Aug 21	\$60,000	\$180,000

Appendix II – Publications & Abstracts, July 1, 2019 – June 30, 2020

Names in bold indicate Arthritis Research Canada/Arthrite-recherche Canada Scientists, trainees and Patient Advisory Board Members

PUBLICATIONS

1. Ahmadian N, Nazarahari M, **Whittaker JL**, Rouhani H. Quantification of triple single-leg hop test temporospatial parameters: A validated method using body-worn sensors for functional evaluation after knee injury. *Sensors (Basel)*. 2020 Jun 19;20(12):3464. doi: 10.3390/s20123464.
2. Amlani A, **Barber CEH**, Fifi-Mah A, Monzon J. Successful treatment of cytokine release syndrome with IL-6 Blockade in a patient transitioning from Immune-Checkpoint to MEK/BRAF Inhibition: A case report and review of literature. *Oncologist* 2020 Jul;25(7):e1120-e1123.
3. **Bansback N**, Curtis JR, Huang J, He Z, Evans M, Johansson T, Michaud K, Schmajuk G, Liao KP. Patterns of tumor necrosis factor inhibitor (TNFi) biosimilar use across United States rheumatology practices. *ACR Open Rheumatol*. 2020 Feb;2(2):79-83. doi: 10.1002/acr2.11106. Epub 2020 Jan 6.
4. **Barber CE**, Lix L, **Lacaille D**, **Marshall DA**, Kroeker K, **Benseler S**, Twilt M, Schmeling H, **Barnabe C**, **Hazlewood G**, Bykerk V, Homik J, Thorne JC, Burt J, Mosher D, Katz S, Shiff N. Testing population-based performance measures identifies gaps in juvenile idiopathic arthritis (JIA) care. *BMC Health Serv Res*. 2019 Aug 14;19(1):572. doi: 10.1186/s12913-019-4379-4.
5. **Barber CE**, **Marshall DA**, Szefer E, **Barnabe C**, Shiff N, Bykerk V, Homik J, Thorne C, Ahluwalia V, Benseler S, Mosher D, Twilt M, **Lacaille D**. A population-based approach to reporting system-level performance measures for rheumatoid arthritis care. *Arthritis Care Res (Hoboken)*. 2020 Mar 7. doi: 10.1002/acr.24178. Online ahead of print.
6. **Barber CEH**, **Barnabe C**, **Benseler S**, Chin R, Johnson N, Luca N, Miettunen P, Twilt M, Veeramreddy D, Shiff NJ, Schmeling H. Patient factors associated with waiting time to pediatric rheumatologist consultation for patients with juvenile idiopathic arthritis. *Pediatr Rheumatol Online J*. 2020 Mar 6;18(1):22. doi: 10.1186/s12969-020-0413-7.
7. **Barber CEH**, Zell J, Yazdany J, Davis AM, Cappelli L, Ehrlich-Jones L, Everix D, Thorne JC, Bohm V, Suter L, Limanni A, Michaud K. 2019 American College of Rheumatology recommended patient-reported functional status assessment measures in rheumatoid arthritis. *Arthritis Care Res (Hoboken)*. 2019 Dec;71(12):1531-1539. doi: 10.1002/acr.24040. Epub 2019 Nov 11.
8. **Barber CE**, Twilt M, Pham T, Currie GR, **Benseler S**, Yeung RSM, Batthish M, Blanchette N, Guzman J, Lang B, LeBlanc C, Levy DM, O'Brien C, Schmeling H, Soon G, Spiegel L, Whitney K, **Marshall DA**. A Canadian evaluation framework for quality improvement in childhood arthritis: key performance indicators of the process of care. *Arthritis Research and Therapy*, March 2020;22(1):53.

9. **Barber MRW**, Hanly JG, Su L, Urowitz MB, St Pierre Y, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, **Fortin PR**, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Farewell V, Stoll T, Buyon J, Clarke AE. Economic evaluation of damage accrual in an international SLE inception cohort using a multi-state model approach. *Arthritis Care Res (Hoboken)*. 2019 Oct 14. doi: 10.1002/acr.24092. [Epub ahead of print].
10. **Barnabe C**, Miller J, Teare S, Eaglespeaker C, Roland B, Eshkakogan N, Crowshoe L, **Lopatina E**, **Marshall D**. Solution model for enhancing the experiences of Urban First Nations and Métis patients accessing and navigating the health system for inflammatory arthritis care. *The International Indigenous Policy Journal*. 2019;10(2). <https://doi.org/10.18584/iipj.2019.10.2.3>.
11. **Bartlett SJ**, De Leon E, Orbai AM, Haque UJ, Manno RL, Ruffing V, Butanis A, Duncan T, Jones MR, Leong A, Perin J, Smith KC, Bingham CO. Patient-reported outcomes in rheumatoid arthritis care improve patient communication, decision-making, satisfaction and confidence: qualitative results. *Rheumatology (Oxford)*. *Rheumatology (Oxford)*. 2020 Jul 1;59(7):1662-1670.
12. **Bartlett SJ**, Lambert SD, McCusker J, Yaffe M, de Raad M, Belzile E, Ciampi A, Di Carlo M, Lyddiatt A. Self-management across chronic diseases: Targeting education and support needs. *Patient Educ Couns*. 2020 Feb;103(2):398-404. doi: 10.1016/j.pec.2019.08.038. Epub 2019 Sep 6.
13. Batthish M, Berard R, Cabral D, Bolaria R, Chédeville G, Duffy C, Gerhold K, Gerschman T, Huber A, Proulx-Gauthier JP, Rosenberg A, Rumsey D, Schmeling H, Shiff N, Soon G, Bruns A, Tucker L, Guzman J, **Benseler SJ**; Canadian Alliance of Pediatric Rheumatology Investigators. A new Canadian inception cohort for juvenile idiopathic arthritis: The Canadian Alliance of Pediatric Rheumatology Investigators Registry. *Rheumatology (Oxford)*. 2020 Feb 11. pii: keaa006. doi: 10.1093/rheumatology/keaa006. [Epub ahead of print].
14. Becce F, Ghoshhajra B, **Choi HK**. Identification of cardiovascular monosodium urate crystal deposition in patients with gout using dual-energy computed tomography. *JAMA Cardiol*. 2020 Feb 5. doi: 10.1001/jamacardio.2019.5804. [Epub ahead of print] No abstract available.
15. Becetti K, Kwakkenbos L, Carrier ME, Gordon JK, Nguyen JT, Mancuso CA, Mouthon L, Nguyen C, Rannou F, Welling J, Thombs BD, Spiera RF; SPIN Investigators (includes **Hudson M**). Physical or occupational therapy use in systemic sclerosis: A Scleroderma Patient-centered Intervention Network Cohort Study. *J Rheumatol*. 2019 Dec;46(12):1605-1613. doi: 10.3899/jrheum.181130. Epub 2019 May 1.

16. Belton J, **Hoens A**, Scott A, Ardern CL. Patients as partners in research: It's the right thing to do. *Journal of Orthopaedic & Sports Physical Therapy*. 2019 49(9), 623-626.
17. Bersellini Farinotti A, Wigerblad G, Nascimento D, Bas DB, Morado Urbina C, Nandakumar KS, Sandor K, Xu B, Abdelmoaty S, **Hunt MA**, Ängeby Möller K, Baharpoor A, Sinclair J, Jardemark K, Lanner JT, Khmaladze I, Borm LE, Zhang L, Wermeling F, Cragg MS, Lengqvist J, Chabot-Doré AJ, Diatchenko L, Belfer I, Collin M, Kultima K, Heyman B, Jimenez-Andrade JM, Codeluppi S, Holmdahl R, Svensson CI. Cartilage-binding antibodies induce pain through immune complex-mediated activation of neurons. *J Exp Med*. 2019 Aug 5;216(8):1904-1924.
18. Biggs CM, Modi B, Steinraths M, Del Bel K, Pourshahnazari P, Griffiths C, Forrest DM, Prendiville J, **Dutz JP**, Turvey SE, Cameron SB. Recurrent sterile abscesses in a case of X-linked neutropenia. *Pediatr Dermatol*. 2020 Jul;37(4):742-744. doi: 10.1111/pde.14146.
19. Boocock J, Leask M, Okada Y; Asian Genetic Epidemiology Network (AGEN) Consortium, Matsuo H, Kawamura Y, Shi Y, Li C, Mount DB, Mandal AK, Wang W, Cadzow M, Gosling AL, Major TJ, Horsfield JA, **Choi HK**, Fadason T, O'Sullivan J, Stahl EA, Merriman TR. Genomic dissection of 43 serum urate-associated loci provides multiple insights into molecular mechanisms of urate control. *Hum Mol Genet*. 2020 Apr 15;29(6):923-943. doi: 10.1093/hmg/ddaa013.. [
20. Bosman ES, Albert AY, Lui H, **Dutz JP**, Vallance BA. Skin exposure to narrow band ultraviolet (UVB) light modulates the human intestinal microbiome. *Front Microbiol*. 2019 Oct 24;10:2410. doi: 10.3389/fmicb.2019.02410. eCollection 2019.
21. **Brunet SC**, Kuczynski MT, Bhatla JL, Lemay S, Pauchard Y, Salat P, **Barnabe C**, Manske SL. The utility of multi-stack alignment and 3D longitudinal image registration to assess bone remodeling in rheumatoid arthritis patients from second generation HR-pQCT scans. *BMC Med Imaging*. 2020 Apr 7;20(1):36. doi: 10.1186/s12880-020-00437-8.
22. Bursill D, Taylor WJ, Terkeltaub R, Abhishek A, So AK, Vargas-Santos AB, Gaffo AL, Rosenthal A, Tausche AK, Reginato A, Manger B, Sciré C, Pineda C, van Durme C, Lin CT, Yin C, Albert DA, Biernat-Kaluza E, Roddy E, Pascual E, Becce F, Perez-Ruiz F, Sivera F, Lioté F, Schett G, Nuki G, Filippou G, McCarthy G, da Rocha Castelar Pinheiro G, Ea HK, Tupinambá HA, Yamanaka H, **Choi HK**, et al and the. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. *Ann Rheum Dis*. 2019 Nov;78(11):1592-1600. doi: 10.1136/annrheumdis-2019-215933. Epub 2019 Sep 9.
23. Carr ECJ, Ortiz MM, Patel JN, **Barber CEH**, Katz S, Robert J, Mosher D, Teare SR, Miller J, Homik J, Dinsmore K, **Marshall DA**. Models of arthritis care: a systems-level evaluation of acceptability as a dimension of quality of care. *J Rheumatol*. 2019 Nov 15. pii: jrheum.190501. doi: 10.3899/jrheum.190501. [Epub ahead of print]

24. Carrier ME, Kwakkenbos L, Nielson WR, Fedoruk C, Nielsen K, Milette K, Pope J, Frech T, Gholizadeh S, Hummers L, Johnson SR, Piotrowski P, Jewett L, Gordon J, Chung L, Bilsker D, Turner KA, Cumin J, Welling J, Fortune C, Leite C, Gottesman K, Sauve M, Rodríguez-Reyna TS, **Hudson M**, Larche M, van Breda W, Suarez-Almazor ME, **Bartlett SJ**, Malcarne VL, Mayes MD, Boutron I, Mouthon L, Wigley F, Thombs BD; SPIN Investigators. The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial. *JMIR Res Protoc*. 2020 Apr 24;9(4):e16799. doi: 10.2196/16799.
25. Cesaro A, Defrêne J, Lachhab A, Pagé N, Tardif MR, Al-Shami A, Oravec T, **Fortin PR**, Daudelin JF, Labrecque N, Aoudjit F, Pelletier M, Tessier PA. Enhanced myelopoiesis and aggravated arthritis in S100a8-deficient mice. *PLoS One*. 2019 Aug 22;14(8):e0221528. doi: 10.1371/journal.pone.0221528. eCollection 2019.
26. Chan C, Inskip JA, Kirkham AR, Anserimo M, Dumont G, Li L, Ho K, Novak-Lauscher H, Ryerson CJ, **Hoens AM**, Chen P, Garde A, Road JD, Camp PG. A smartphone oximeter with a fingertip probe for use during exercise training: usability, validity and reliability in individuals with chronic lung disease and controls. *Physiotherapy*. 2019. 105(3), 297-306.
27. **Chen SK**, Voaklander D, Perry D, **Jones CA**. Falls and fear of falling in older adults with total joint arthroplasty: a scoping review. *BMC Musculoskelet Disord*. 2019 Dec 12;20(1):599. doi: 10.1186/s12891-019-2954-9.
28. Chew C, **Rebić N**, Baldwin C, Amiri N, Proulx L, **De Vera MA**. Arthritis, Pregnancy, and Parenting: A qualitative descriptive study of Reddit Forums to explore information needs and concerns of women with rheumatoid arthritis. *ACR Open Rheumatol*. 2019 Aug 15;1(8):485-492. doi: 10.1002/acr2.11069. eCollection 2019 Oct.
29. Choi C, Moller D, Tan J, Dou C, Peterson EA, Medvedev N, **Dutz JP**, **Carruthers MN**, Chen LYC. Pegylated interferon alpha 2a is an effective and well-tolerated treatment option for lymphocyte-variant hypereosinophilic syndrome. *Br J Haematol*. 2020 Mar;188(5):e68-e72. doi: 10.1111/bjh.16332. Epub 2019 Nov 13.
30. **Choi MY**, Fritzler MJ. Autoantibodies in SLE: prediction and the p value matrix. *Lupus*. 2019 Oct;28(11):1285-1293. doi: 10.1177/0961203319868531. Epub 2019 Aug 9.
31. **Choi HK**, **McCormick N**, **Lu N**, **Rai SK**, Yokose C, **Zhang Y**. Population impact attributable to modifiable risk factors for hyperuricemia. *Arthritis Rheumatol*. 2020 Jan;72(1):157–65.
32. Conner-Spady B, Bohm E, Loucks L, Dunbar M, **Marshall DA**. Patient expectations and satisfaction 6 and 12 months following total hip and knee replacement. *Quality of Life Research*. 2020; 29(3):705-719.
33. Cox SM, McDonald M, **Townsend A**. Epistemic strategies in ethical review: REB members' experiences of assessing probable impacts of research for human subjects. *J Empir Res Hum Res Ethics*. 2019 Sep 15:1556264619872369. doi: 10.1177/1556264619872369. [Epub ahead of print].

34. Craig ET, Perin J, Zeger S, Curtis JR, Bykerk VP, Bingham CO, **Bartlett SJ**. What does the patient global health assessment in RA really tell us? Contribution of specific dimensions of health-related quality of life. *Arthritis Care Res (Hoboken)*. 2019 Sep 24. doi: 10.1002/acr.24073. [Epub ahead of print].
35. Dalbeth N, **Choi HK**, Joosten LAB, Khanna PP, Matsuo H, Perez-Ruiz F, Stamp LK. Gout. *Nat Rev Dis Primers*. 2019 Sep 26;5(1):69. doi: 10.1038/s41572-019-0115-y. Review.
36. Danieli C, Sheppard T, Costello R, Dixon WG, **Abrahamowicz M**. Modeling of cumulative effects of time-varying drug exposures on within-subject changes in a continuous outcome. *Stat Methods Med Res*. 2020 Sep;29(9):2554-2568. doi: 10.1177/0962280220902179. Epub 2020 Feb 5.
37. de Jesus AA, Hou Y, Brooks S, Malle L, Biancotto A, Huang Y, Calvo KR, Marrero B, Moir S, Oler AJ, Deng Z, Montealegre Sanchez GA, Ahmed A, Allenspach E, Arabshahi B, Behrens E, **Benseler S**, et al. Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. *J Clin Invest*. 2020 Apr 1;130(4):1669-1682. doi: 10.1172/JCI129301.
38. Dhillon N, Skinnider B, Darabian S, **Carruthers M**. Histiocytosis masquerading in the mesentery and pleura. *BMJ Case Rep*. 2019 Dec 1;12(11). pii: e232165. doi: 10.1136/bcr-2019-232165.
39. DiRenzo DD, Craig ET, Bingham lii CO, **Bartlett SJ**. Anxiety impacts rheumatoid arthritis symptoms and health-related quality of life even at low levels. *Clin Exp Rheumatol*. 2020 Mar 5. [Epub ahead of print].
40. Durand C, Maysoon E, **Marshall DA, Bansback N, Hazlewood G**. Patient preferences for disease-modifying antirheumatic drug treatment in rheumatoid arthritis: A systematic review. *J Rheumatol*. 2020;47(2):176-187.
41. Efthymiou M, Mackie IJ, Lane PJ, Andradr D, Willis R, Erkan D, Sciascia S, Krillis S, Bison E, Borges Galhardo Vendramini M, Romay-Penabad Z, Qi M, Tektonidou M, Ugarte A, Chighizola C, Belmont HM, Aguirre MA, Ji L, Branch DW, de Jesus G, **Fortin PR**, Andreoli L, Petri M, Cervera R, Rodriguez E, Knight JS, Atsumi T, Vega J, Ecem S, Bertolaccini ML, Pengo V, Cohen H. APS ACTION. Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome (APS) Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. *J Thromb Haemost*. 2019 Dec;17(12):2069-2080. doi: 10.1111/jth.14596. Epub 2019 Sep 8.
42. Ellingwood L, Schieir O, Valois MF, **Bartlett SJ**, Bessette L, Boire G, **Hazlewood G**, Hitchon C, Keystone EC, Tin D, Thorne C, Bykerk VP, Pope JE, **Colmegna I**; CATCH Investigators. Palindromic Rheumatism Frequently Precedes Early Rheumatoid Arthritis: Results From an Incident Cohort. *ACR Open Rheumatol*. 2019 Oct 21;1(10):614-619. doi: 10.1002/acr2.11086. eCollection 2019 Dec.

43. Ellingwood L, Kudaeva F, Schieir O, **Bartlett SJ**, Bessette L, Boire G, **Hazlewood GS**, Hitchon C, Keystone E, Tin D, Thorne C, Bykerk VP, Pope J; **Colmegna I**, CATCH Investigators. A quarter of patients time their early rheumatoid arthritis onset differently than physicians. *RMD Open*. 2019 Nov 14;5(2):e000931. doi: 10.1136/rmdopen-2019-000931. eCollection 2019.
44. Enocsson H, Wirestam L, Dahle C, Padyukov L, Jönsen A, Urowitz MB, Gladman DD, Romero-Diaz J, Bae SC, **Fortin PR**, Sanchez-Guerrero J, **Clarke AE**, Bernatsky S, Gordon C, Hanly JG, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Ginzler E, Alarcón GS, Chatham WW, Petri M, Khamashta M, Aranow C, Mackay M, Dooley MA, Manzi S, Ramsey-Goldman R, Nived O, Steinsson K, Zoma AA, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, van Vollenhoven RF, Ramos-Casals M, Kamen DL, Jacobsen S, Peschken CA, Askanase A, Stoll T, Bruce IN, Wetterö J, Sjöwall C. Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. *J Autoimmun*. 2020 Jan;106:102340. doi: 10.1016/j.jaut.2019.102340. Epub 2019 Oct 17.
45. **Esculier JF**, Jarrett M, Krowchuk NM, Rauscher A, Wiggermann V, Taunton JE, Wilson DR, Gatti AA, **Hunt MA**. Cartilage recovery in runners with and without knee osteoarthritis: A pilot study. *Knee*. 2019 Oct;26(5):1049-1057. doi: 10.1016/j.knee.2019.07.011. Epub 2019 Aug 18.
46. Esfahani K, **Hudson M**, Batist G. Tofacitinib for refractory immune-related colitis from PD-1 therapy. *N Engl J Med*. 2020 Jun 11;382(24):2374-2375. doi: 10.1056/NEJMc2002527.
47. Esfahani K, Al-Aubodah TA, Thebault P, Lapointe R, **Hudson M**, Johnson NA, Baran D, Bhulaiga N, Takano T, Cailhier JF, Piccirillo CA, Miller WH. Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation. *Nat Commun*. 2019 Oct 17;10(1):4712. doi: 10.1038/s41467-019-12628-1.
48. Ezzat AM, **Whittaker JL**, Brussoni M, Mâsse LC, Emery CA. The English Knee Self-Efficacy Scale is a valid and reliable measure for knee-specific self-efficacy in individuals with a sport-related knee injury in the past five years. *Knee Surg Sport Traumatol Arthrosc*. Online First: April 17 2020 doi: 10.1007/s00167-020-05974-x.
49. Fenwick EK, **Bansback N**, Gan ATL, Ratcliffe J, Burgess L, Wong TY, Lamoureux EL. Validation of a novel diabetic retinopathy utility index using discrete choice experiments. *Br J Ophthalmol*. 2020 Feb;104(2):188-193. doi: 10.1136/bjophthalmol-2019-313899. Epub 2019 May 16.

50. Fortuné C, Gietzen A, Guillot G, Lewis N, Nielsen K, Richard M, Sauvé M, Welling J; SPIN Investigators, Baron M, Furst DE, Gottesman K, Malcarne V, Mayes MD, Mouthon L, Nielson WR, Riggs R, Wigley F, Assassi S, Boutron I, Ells C, van den Ende C, Fligelstone K, Frech T, Godard D, Harel D, Hinchcliff M, **Hudson M, Fortin PR**, et al and the Scleroderma Patient-centered Intervention Network (SPIN); COVID-19 Patient Advisory Team. Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients. *J Psychosom Res*. 2020 May 14;110132. doi: 10.1016/j.jpsychores.2020.110132. [Epub ahead of print].
51. Gignac MAM, Irvin E, Cullen K, Van Eerd D, Beaton DE, Mahood Q, McLeod C, **Backman CL**. Men and women's occupational activities and the risk of developing osteoarthritis of the knee, hip or hands: A systematic review and recommendations for future research. *Arthritis Care Res (Hoboken)*. 2020 Mar;72(3):378-396. doi: 10.1002/acr.23855.
52. Goplen CM, Randall JR, Kang SH, Vakilian F, **Jones CA**, Voaklander DC, Beaupre LA. The influence of allowable refill gaps on detecting long-term opioid therapy: An analysis of population-based administrative dispensing data among patients with knee arthritis awaiting total knee arthroplasty. *J Manag Care Spec Pharm*. 2019 Oct;25(10):1064-1072. doi: 10.18553/jmcp.2019.25.10.1064.
53. Goplen CM, Verbeek W, Kang SH, **Jones CA**, Voaklander DC, Churchill TA, Beaupre LA. Preoperative opioid use is associated with worse patient outcomes after Total joint arthroplasty: a systematic review and meta-analysis. *BMC Musculoskelet Disord*. 2019 May 18;20(1):234. doi: 10.1186/s12891-019-2619-8.
54. **Grazziotin Lago L**, Currie G, Kip MMA, IJzerman MJ, Twilt M, Lee R, **Marshall DA**. Health state utilities values in juvenile idiopathic arthritis: What is the evidence? *PharmacoEconomics*. 2020 Sep;38(9):913-926. doi: 10.1007/s40273-020-00921-7.
55. **Hamilton C**, Snow ME, Clark N, Gibson S, Dehnadi M, Lui M, Koster A, McLean J, **Li LC**. Quality of patient, family, caregiver and public engagement in decision-making in healthcare systems: a scoping review protocol. *BMJ Open*. 2019 Nov 6;9(11):e032788. doi: 10.1136/bmjopen-2019-032788.
56. Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, **Clarke AE**, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, **Fortin PR**, et al. Peripheral nervous system disease in systemic lupus erythematosus: results from an international, inception cohort study. *Arthritis Rheumatol*. 2020 Jan;72(1):67-77. doi: 10.1002/art.41070. Epub 2019 Nov 28.

57. Hanly JG, Urowitz MB, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, **Clarke AE**, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, **Fortin PR**, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, Alarcón GS, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Lim S, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Farewell V. Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. *Ann Rheum Dis*. 2020 Mar;79(3):356-362. doi: 10.1136/annrheumdis-2019-216150. Epub 2020 Jan 8.
58. Hansmann S, Lainka E, Horneff G, Holzinger D, Rieber N, Jansson AF, Rösen-Wolff A, Erbis G, Prelog M, Brunner J, **Benseler SM**, Kuemmerle-Deschner JB. Consensus protocols for the diagnosis and management of the hereditary autoinflammatory syndromes CAPS, TRAPS and MKD/HIDS: a German PRO-KIND initiative. *Pediatr Rheumatol Online J*. 2020 Feb 17;18(1):17. doi: 10.1186/s12969-020-0409-3.
59. Harb S, Cumin J, Rice DB, Peláez S, **Hudson M**, **Bartlett SJ**, Roren A, Furst DE, Frech TM, Nguyen C, Nielson WR, Thombs BD, Shrier I; Scleroderma Patient-centered Intervention Network – Physical Activity Enhancement Patient Advisory Team. Identifying barriers and facilitators to physical activity for people with scleroderma: a nominal group technique study. *Disabil Rehabil*. 2020 Mar 19:1-8. doi: 10.1080/09638288.2020.1742391. Online ahead of print.
60. Harford W, **Backman CL**, **Li LC**, **McKinnon A**, Nimmon L. Appropriating and asserting power on inflammatory arthritis teams: a social network perspective. *Health Expect*. 2020 Mar 17. doi: 10.1111/hex.13051. Online ahead of print.
61. **Harrison M**, Quisias J, Frew EJ, Albon SP. A cost-benefit analysis of teaching and learning technology in a faculty of pharmaceutical sciences. *Am J Pharm Educ*. 2019 Aug;83(6):6834. doi: 10.5688/ajpe6834.
62. **Harrison M**, **Bansback N**, Aguiar M, **Koehn C**, **Shojania K**, Finckh A, **Hudson M**. Preferences for treatments to prevent rheumatoid arthritis in Canada and the influence of shared decision-making. *Clin Rheumatol*. 2020 Apr 4. doi: 10.1007/s10067-020-05072-w. Online ahead of print.
63. **Hazlewood GS**, Niaki OZ, Fitzcharles MA. Cannabis for rheumatic pain: hope or hype? *Clin Rheumatol*. 2019 Oct;38(10):2655-2657. doi: 10.1007/s10067-019-04658-3. Epub 2019 Jul 5.
64. **Hazlewood GS**, Pokharel G, Deardon R, **Marshall DA**, Bombardier C, Tomlinson G, Ma C, Seow CH, Panaccione R, Kaplan GG. Patient preferences for maintenance therapy in Crohn's disease: A discrete-choice experiment. *PLoS One*. 2020 Jan 16;15(1):e0227635. doi: 10.1371/journal.pone.0227635. eCollection 2020.
65. **Hazlewood GS**, **Marshall DA**, **Barber CEH**, **Li LC**, **Barnabe C**, Bykerk V, Tugwell P, Hull PM, **Bansback N**. Using a discrete-choice experiment in a decision aid to nudge patients towards value-concordant treatment choices in rheumatoid arthritis: A proof-of-concept study. *Patient Preference and Adherence*, 2020 1:1(4)1-10.

66. He C, Levis B, Riehm KE, Saadat N, Levis AW, Azar M, Rice DB, Krishnan A, Wu Y, Sun Y, Imran M, Boruff J, Cuijpers P, Gilbody S, Ioannidis JPA, Kloda LA, McMillan D, Patten SB, Shrier I, Ziegelstein RC, Akena DH, Arroll B, Ayalon L, Baradaran HR, Baron M, Beraldi A, Bombardier CH, Butterworth P, Carter G, **Hudson M**, et al. The Accuracy of the Patient Health Questionnaire-9 Algorithm for screening to detect major depression: An individual participant data meta-analysis. *Psychother Psychosom.* 2020;89(1):25-37. doi: 10.1159/000502294. Epub 2019 Oct 8.
67. Henrey A, Rypdal V, Rypdal M, Loughin T, Nordal E, Guzman J, **Benseler SJ**; ReACCh-Out and NoSPeR Investigators. Validation of prediction models of severe disease course and non-achievement of remission in juvenile idiopathic arthritis part 2: results of the Nordic model in the Canadian cohort. *Arthritis Res Ther.* 2020 Jan 15;22(1):10. doi: 10.1186/s13075-019-2091-8.
68. Hoa S, Bernatsky S, Steele RJ, Baron M, **Hudson M**; Canadian Scleroderma Research Group. Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis. *Rheumatology (Oxford).* 2020 May 1;59(5):1108-1117. doi: 10.1093/rheumatology/kez407.
69. **Howren A, Aviña-Zubieta JA**, Puyat JH, **Esdale JM, Da Costa D, De Vera MA**. Defining depression and anxiety in individuals with inflammatory arthritis using administrative health databases: A systematic review. *Arthritis Care Res (Hoboken).* 2020 Feb;72(2):243-255. doi: 10.1002/acr.24048. Epub 2020 Jan 9.
70. **Howren A, Tsao NW, Choi HK, Shojan K**, Kydd A, Friesen R, **Aviña-Zubieta JA, De Vera MA**. eHealth-supported decentralized multi-disciplinary care for gout involving rheumatology, pharmacy, and dietetics: proof-of-concept study. *Clin Rheumatol.* 2020 Apr;39(4):1241-1249. doi: 10.1007/s10067-019-04809-6. Epub 2019 Nov 13.
71. **Howren A**, Bowie D, **Choi HK, Rai SK, De Vera MA**. Epidemiology of depression and anxiety in gout: A systematic review and metaanalysis. *J Rheumatol.* 2020 Mar 1. pii: jrheum.190974. doi: 10.3899/jrheum.190974. [Epub ahead of print].
72. Holt C, McKay C, **Truong L, Le CY**, Gross D, **Whittaker JL**. 'Sticking to it' A scoping review of adherence to exercise therapy interventions in children and adolescents. *J Orthop Sport Phys Ther.* 2020 Aug 1;1-54. doi: 10.2519/jospt.2020.9715. Online ahead of print.
73. **Howren A, Rebić N, Sayre EC**, Tsao NW, Amiri N, Baldwin C, **De Vera MA**. Perinatal exposure to conventional synthetic disease-modifying anti-rheumatic drugs in women with rheumatic disease and neonatal outcomes: a population-based study. *Clin Exp Rheumatol.* 2020 Mar 5. Online ahead of print.
74. Huang T, Wang T, Heianza Y, Wiggs J, Sun D, **Choi HK**, Chai JF, Sim X, Khor CC, Friedlander Y, Chan AT, Curhan G, Vivo I, van Dam RM, Heng CK, Fuchs C, Pasquale LR, Yuan JM, Hu FB, Koh WP, Qi L. Fish and marine fatty acids intakes, the FADS genotypes and long-term weight gain: a prospective cohort study. *BMJ Open.* 2019 Jul 31;9(7):e022877. doi: 10.1136/bmjopen-2018-022877.

75. Huang K, Vinik O, **Shojania K**, Yeung J, Shupak R, Nimmo M, **Aviña-Zubieta JA**. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation associated gene 5 (MDA5) Positive Dermatomyositis: a case based review. *Rheum Int*. 2019 Nov;39(11):1971-1981.
76. Huang K, Levy RD, **Aviña-Zubieta JA**. Successful lung transplant in rapid progressive interstitial lung disease associated with anti-melanoma differentiation associated gene 5. *Rheumatology (Oxford)*. 2020 Aug 1;59(8):2161-2163. doi: 10.1093/rheumatology/keaa032.
77. **Hudson M**, Dell'Aniello S, Shen S, Simon TA, Ernst P, Suissa S. Comparative safety of biologic versus conventional synthetic DMARDs in rheumatoid arthritis with COPD: a real-world population study. *Rheumatology (Oxford)*. 2020 Apr 1;59(4):820-827.
78. **Hunt MA, Charlton JM, Esculier JF**. Osteoarthritis year in review 2019: mechanics. *Osteoarthritis Cartilage*. 2020 Mar;28(3):267-274. doi: 10.1016/j.joca.2019.12.003. Epub 2019 Dec 23. Review.
79. Irigorri N, **Hazlewood G**, Manns B, Bojke L, Spackman E; PROMPT study group. A model to determine the cost-effectiveness of screening psoriasis patients for psoriatic arthritis. *Arthritis Care Res (Hoboken)*. 2019 Nov 15. doi: 10.1002/acr.24110. [Epub ahead of print].
80. **Jamal S, Hudson M**, Fifi-Mah A, Ye C. Immune-related adverse events associated with cancer immunotherapy: a review for the practicing rheumatologist. *J Rheumatol*. 2020 Feb;47(2):166-175. doi: 10.3899/jrheum.190084. Epub 2019 Jul 15.
81. **Jones CA**, Forhan M. Addressing weight bias and stigma of obesity amongst physiotherapists. *Physiother Theory Pract*. 2019 Jul 31:1-9. doi: 10.1080/09593985.2019.1648623. [Epub ahead of print].
82. Jorge A, **McCormick N, Lu L, Esdaile J, De Vera M, Choi H, Avina-Zubieta JA**. Hydroxychloroquine and mortality among patients with systemic lupus erythematosus in the general population. *Arthritis Care Res (Hoboken)*. 2020 May 14. doi: 10.1002/acr.24255. [Epub ahead of print].
83. Kaal KJ, **Bansback N, Hudson M, Anis A, Koehn C, Harrison M**. Patient-provider communication about medication cost in rheumatoid arthritis. *Clin Rheumatol*. 2020 Jun 6. doi: 10.1007/s10067-020-05188-z. Online ahead of print.
84. Kaplan GG, **Aviña-Zubieta JA** et al. Longitudinal trends in the direct costs and health care utilization ascribable to inflammatory bowel disease in the biologic era: results from a Canadian population based analysis. *American Journal of Gastroenterology*. 2020 Jan;115(1):128-137. doi: 10.14309/ajg.0000000000000503.

85. Kelly A, Crimston-Smith L, Tong A, Bartlett SJ, Bekker C, Christensen R, **De Vera MA**, de Wit M, Evans V, Gill M, March L, Manera K, Nieuwlaat R, **Salmasi S**, Scholte-Voshaar M, Singh JA, Sumpton D, Toupin-April K, Tugwell P, van den Bemt B, Verstappen S, Tymms K. Scope of outcomes in trials and observational studies of interventions targeting medication adherence in rheumatic conditions: a systematic review. *Rheumatol*. 2019 Dec 15. pii: jrheum.190726. doi: 10.3899/jrheum.190726. [Epub ahead of print].
86. Kelly A, Tymms K, de Wit M, **Bartlett SJ**, Cross M, Dawson T, **De Vera M**, Evans V, Gill M, Hassett G, Lim I, Manera K, Major G, March L, O'Neill S, Scholte-Voshaar M, Sinnathurai P, Sumpton D, Teixeira-Pinto A, Tugwell P, van den Bemt B, Tong A. Patient and caregiver priorities for medication adherence in gout, osteoporosis and rheumatoid arthritis: nominal group technique. *Arthritis Care Res (Hoboken)*. 2019 Jul 19. doi: 10.1002/acr.24032. [Epub ahead of print].
87. King L, **Marshall DA**, Faris P, Woodhouse L, **Jones CA**, Noseworthy T, Bohm E, Dunbar M, Hawker GA. on behalf of the BEST-Knee team. Use of recommended non-surgical knee osteoarthritis management in patients prior to total knee arthroplasty: a cross-sectional study. *J Rheumatol*. 2020 Aug 1;47(8):1253-1260. doi: 10.3899/jrheum.190467. Epub 2019 Nov 15.
88. **Kopec JA**, Hong Q, Wong H, Zhang CJ, Ratzlaff C, **Cibere J**, **Li LC**, Prlic H, Wilson DR, Forster BB, **Esdaile JM**. Prevalence of femoroacetabular impingement syndrome among young and middle-aged Caucasian adults. *J Rheumatol*. 2019 Nov 1. pii: jrheum.190345. doi: 10.3899/jrheum.190345. [Epub ahead of print]
89. Kuemmerle-Deschner JB, Welzel T, Hoertnagel K, Tsiflikas I, Hospach A, Liu X, Schlipf S, Hansmann S, Samba SD, Griesinger A, **Benseler SM**, Weber AN. New variant in the IL1RN-gene (DIRA) associated with late-onset, CRMO-like presentation. *Rheumatology (Oxford)*. 2020 Apr 7:keaa119. doi: 10.1093/rheumatology/keaa119. Online ahead of print.
90. Kuntze G, Nettel-Aguirre A, Brooks J, Esau S, Nesbitt C, Mosher D, Twilt M, **Benseler S**, Ronsky JL, Emery CA. Consequences of juvenile idiopathic arthritis on single leg squat performance in youth. *Arthritis Care Res (Hoboken)*. 2020 May 14. doi: 10.1002/acr.24254. Online ahead of print.
91. Kuntze G, Nettel-Aguirre A, Brooks J, Esau S, Nesbitt C, Mosher D, Twilt M, **Benseler S**, Ronsky JL, Emery CA. Vertical drop jump performance in youth with juvenile idiopathic arthritis *Arthritis Care Res (Hoboken)*. 2020 Apr 15. doi: 10.1002/acr.24219. Online ahead of print.
92. Kuriya B, Schieir O, Valois MF, Pope JE, Boire G, Bessette L, **Hazlewood G**, Thorne JC, Tin D, Hitchon C, **Bartlett SJ**, Keystone EC, Bykerk VP, Barra L; CATCH investigators. Prevalence and characteristics of metabolic syndrome differ in men and women with early rheumatoid arthritis. *ACR Open Rheumatol*. 2019 Aug 28;1(9):535-541. doi: 10.1002/acr2.11075. eCollection 2019 Nov. Erratum in: *ACR Open Rheumatol*. 2020 Jan;2(1):61.

93. Kwakkenbos L, Cumin J, Carrier ME, **Bartlett SJ**, Malcarne VL, Mouthon L, Nielson WR, Rannou F, Welling J, Thombs BD; **Fortin PR, Hudson M**; SPIN Investigators Δ . Factors associated with patient-reported likelihood of using online self-care interventions: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. *BMJ Open*. 2019 Oct 14; 9(10):e029542. doi: 10.1136/bmjopen-2019-029542.
94. Lai JCY, Cheng WK, Hopkins PD, Komba M, Carlow DA, **Dutz JP**. Topical Adjuvant Application during Subcutaneous Vaccination Promotes Resident Memory T Cell Generation. *J Immunol*. 2019 Nov 1;203(9):2443-2450. doi: 10.4049/jimmunol.1900199. Epub 2019 Oct 2.
95. Leclair V, Landon-Cardinal O, Aggarwal R, Bansback N, Campbell C, Feldman BM, Jarry M, McNamara S, White B, **Hudson M**; CIMS Investigators including **Fortin PR**. Proceedings of the 2019 Canadian Inflammatory Myopathy Study Symposium: Clinical Trial Readiness in Myositis. *J Rheumatol*. 2020 Jun 15:jrheum.200480. Epub ahead of print.
96. Legge A, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, Romero-Diaz J, Sanchez-Guerrero J, Wallace DJ, Bernatsky S, **Clarke AE**, Merrill JT, Ginzler EM, **Fortin PR**, Gladman DD, Urowitz MB, Bruce IN, Isenberg DA, Rahman A, Alarcón GS, Petri M, Khamashta MA, Dooley MA, Ramsey-Goldman R, Manzi S, Zoma AA, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, van Vollenhoven RF, Jonsen A, Nived O, Ramos-Casals M, Kamen DL, Kalunian KC, Jacobsen S, Peschken CA, Askanase A, Hanly JG. Prediction of damage accrual in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). *Arthritis Rheumatol*. 2020 Apr;72(4):658-666. doi: 10.1002/art.41144. Epub 2020 Feb 12.
97. Legge A, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, Romero-Diaz j, Sanchez-Guerrero J, Wallace DJ, Bernatsky S, **Clarke AE**, Merrill J, Ginzler E, **Fortin P**, Gladman D, Urowitz M et al. Construction of a frailty index as a novel health measure in systemic lupus erythematosus. *J Rheumatol*. January 2020. 47(1)72-81. Epub ahead of print.
98. Levis B, Sun Y, He C, Wu Y, Krishnan A, Bhandari PM, Neupane D, Imran M, Brehaut E, Negeri Z, Fischer FH, Benedetti A, Thombs BD; Depression Screening Data (DEPRESSD) PHQ Collaboration, Che L, Levis A, Riehm K, Saadat N, Azar M, Rice D, Boruff J, Kloda L, Cuijpers P, Gilbody S, Ioannidis J, McMillan D, Patten S, Shrier I, Ziegelstein R, Moore A, Akena D, Amtmann D, Arroll B, Ayalon L, Baradaran H, Beraldi A, Bernstein C, Bhana A, Bombardier C, Buji RI, Butterworth P, **Hudson M** et al. Accuracy of the PHQ-2 alone and in combination with the PHQ-9 for screening to detect major depression: systematic review and meta-analysis. *JAMA*. 2020 Jun 9;323(22):2290-2300. doi: 10.1001/jama.2020.6504.
99. **Li LC, Feehan LM, Xie H, Lu N**, Shaw C, Gromala D, **Aviña-Zubieta JA**, Koehn C, **Hoens AM, English K, Tam J, Therrien S, Townsend AF**, Noonan G, **Backman CL**. Efficacy of a physical activity counselling program with use of wearable tracker in people with inflammatory arthritis: A randomized controlled trial. *Arthritis Care Res (Hoboken)*. 2020 Apr 5. doi: 10.1002/acr.24199. [Epub ahead of print].

100. **Li LY, McCormick N, Sayre EC, Esdaile J, Lacaille D, Xie H, Choi H, Aviña-Zubieta JA.** Trends of venous thromboembolism risk before and after diagnosis of gout: a general population-based study. *Rheumatology (Oxford)*. 2020 May 1;59(5):1099-1107. doi: 10.1093/rheumatology/kez398.
101. **Li LY, Xie H, Lu N, Esdaile JM, Aviña-Zubieta JA.** The impact of systemic lupus erythematosus on the risk of newly diagnosed hip fracture: a general population-based study. *Arthritis Care & Research*. (Hoboken). 2019 Nov 23. doi: 10.1002/acr.24112. [Epub ahead of print].
102. Li X, Zhang W, Sun H, **Anis AH.** Effects of health status on work exit and absenteeism among the older working population in China: a secondary analysis of a cohort sample. *BMJ Open*. 2019 Sep 9;9(9):e024115. doi: 10.1136/bmjopen-2018-024115.
103. Logan L, McNairn J, Wiart S, Crowshoe L, Henderson R, **Barnabe C.** Creating space for Indigenous healing practices in patient care plans. *Can Med Educ J*. 2020 Mar 16;11(1):e5-e15. doi: 10.36834/cmej.68647. eCollection 2020 Mar.
104. **Loyola-Sanchez A, Hazlewood G,** Crowshoe L, Linkert T, Hull PM, **Marshall DA, Barnabe C.** Qualitative study of treatment preferences for rheumatoid arthritis and pharmacotherapy acceptance: Indigenous patient perspectives. *Arthritis Care Res (Hoboken)*. 2020 Apr;72(4):544-552. doi: 10.1002/acr.23869.
105. Lu T, Klein KO, **Colmegna I,** Lora M, Greenwood CMT, **Hudson M.** Whole-genome bisulfite sequencing in systemic sclerosis provides novel targets to understand disease pathogenesis. *BMC Med Genomics*. 2019 Oct 24;12(1):144. doi: 10.1186/s12920-019-0602-8.
106. Lundon K, Inrig T, Paton M, Shupak R, Kennedy C, McGlynn M, **Barber C.** Measuring advanced/extended practice roles in arthritis and musculoskeletal care in Canada. *ACR Open Rheumatol*. 2020 Apr;2(4):242-250. doi: 10.1002/acr2.11129. Epub 2020 Apr 11.
107. Maksymowych WP, FitzGerald O, Ostergaard M, Homik J, van der Heijde D, Lambert RG, Elkayam O, Ramiro S, Thorne C, Larche MJ, Ferraccioli G, Backhaus M, Burmester GR, Boire G, Combe B, Schaeffer T, Saraux A, Dougados M, Adami S, Govoni M, Sinigaglia L, Cantagrel A, Allaart R, **Barnabe C,** Bingham CO III, Tak PP, van Schaardenburg D, Berner Hammer H, Paschke J, Dadashova R, Hutchings E, Sepriano A, Landewe R. Outcomes and findings of the International Rheumatoid Arthritis BIODAM Cohort for Validation of soluble biomarkers in rheumatoid arthritis. *J Rheumatol*. 2020, 47 (6) 796-808. pii: jrheum.190302. doi: 10.3899/jrheum.190302. [Epub ahead of print].
108. Malone DC, Ramsey SD, Patrick DL, Johnson FR, Mullins CD, Roberts MS, Willke RJ, **Marshall DA.** Criteria and process for initiating and developing an ISPOR Good Practices Task Force Report. *Value in Health*, April 2020;23(4): 409-415.
109. Maltez N, Abdullah A, Fifi-Mah A, **Hudson M, Jamal S** and the Canadian Research Group in Immuno-Oncology (CanRIO). Checking in with immune checkpoint inhibitors: Results of a needs assessment survey of Canadian rheumatologists. *J Cancer Sci Therap*. 2019;2(1):12.

110. Manseer T, Gross DP, Dennet L, Schneider K, **Whittaker JL**. Gait deviations associated with concussion: A systematic review. *Clin J Sport Med* 30:S11-S28.
111. **Marshall DA**, Liu X, **Barnabe C**, Yee K, Faris P, **Barber CEH**, Mosher D, Noseworthy T, Werle J, Lix LM. Existing comorbidities in people with osteoarthritis: a retrospective analysis of a population-based cohort in Alberta, Canada. *BMJ Open*. 2019 Nov 21;9(11):e033334. doi: 10.1136/bmjopen-2019-033334.
112. **Marshall DA**, Pham T, Faris P, Chen G, O'Donnell S, **Barber CE**, LeClercq S, Katz S, Homik J, Patel JN, **Lopatina E**, Roberts J, Mosher D. Determination of rheumatoid arthritis incidence and prevalence in Alberta using administrative health data. *ACR Open Rheumatol*. 2020 Jul;2(7):424-429.
113. **Marshall DA**, **Grazziotin Lago L**, Regier D, Wordsworth S, Buchanan J, Phillips K, IZjerman M. Addressing challenges of economic evaluation in precision medicine using dynamic simulation modelling. *Value in Health*, May 2020;23(5):566-573.
114. Mattman A, Chen LYC, van der Gugten G, Chin A, **Carruthers M**, DeMarco ML, Holmes DT. In IgG4 related disease, elevated IgG2 is an artifact not a biomarker. *Semin Arthritis Rheum*. 2020 Apr;50(2):e8. doi: 10.1016/j.semarthrit.2019.08.002. Epub 2019 Aug 12.
115. **McCormick N**, **Marra CA**, Sadatsafavi M, **Aviña-Zubieta JA**. Socioeconomic status at diagnosis influences the incremental direct medical costs of systemic lupus erythematosus: a longitudinal population-based study. *Semin Arthritis Rheum*. 2020 Feb;50(1):77-83. doi: 10.1016/j.semarthrit.2019.06.010. Epub 2019 Jun 14.
116. **McCormick N**, Wallace ZS, Sacks CA, Hsu J, **Choi HK**. Decomposition analysis of spending and price trends for biologic antirheumatic drugs in Medicare and Medicaid. *Arthritis Rheumatol*. 2020 Feb;72(2):234–41. doi: 10.1002/art.41138. Epub 2020 Jan 6.
117. **McCormick N**. Which patients with rheumatoid arthritis will start biologics, how soon, and why—much to learn from a universal coverage setting [Invited Commentary]. *JAMA Netw Open*. 2019 Dec 6;2(12):e1917065.
118. McDermott G, Fu X, Stone JH, Wallwork R, Zhang Y, **Choi HK**, Wallace ZS. Association of cigarette smoking with antineutrophil cytoplasmic antibody-associated vasculitis. *JAMA Intern Med*. 2020 Apr 13;180(6):1-7. doi: 10.1001/jamainternmed.2020.0675. Online ahead of print.
119. McGrath S, Zhao X, Steele R, Thombs BD, Benedetti A; DEPRESSion Screening Data (DEPRESSD) Collaboration (includes **Hudson M**). Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis. *Stat Methods Med Res*. 2020 Jan 30;962280219889080. doi: 10.1177/0962280219889080. Online ahead of print.
120. Mendel A, Bernatsky S, Thorne JC, **Lacaille D**, Johnson SR, Vinet É. Hydroxychloroquine shortages during the COVID-19 pandemic. *Ann Rheum Dis*. 2020 May 20;annrheumdis-2020-217835. doi: 10.1136/annrheumdis-2020-217835.

121. Meyer A, Troyanov Y, Drouin J, Oligny-Longpré G, Landon-Cardinal O, Hoa S, Hervier B, Bourré-Tessier J, Mansour AM, Hussein S, Morin V, Rich E, Goulet JR, Chartrand S, **Hudson M**, Nehme J, Makhzoum JP, Zarka F, Villeneuve E, Raynauld JP, Landry M, O'Ferrall EK, Ferreira J, Ellezam B, Karamchandani J, Larue S, Massie R, Isabelle C, Deschênes I, Leclair V, Couture H, Targoff IN, Fritzler MJ, Sénécal JL. Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients. *Arthritis Res Ther*. 2020 Jan 8;22(1):5. doi: 10.1186/s13075-019-2093-6.
122. **Michou L**, Orcel P. Has Paget's bone disease become rare? *Joint Bone Spine*. 2019 Oct;86(5):538-541. doi: 10.1016/j.jbspin.2019.01.015. Epub 2019 Feb 4. No abstract available.
123. Mohammadi T, Zhang W, Sou J, Langlois S, Munro S, **Anis AH**. A Hierarchical Bayes Approach to Modeling Heterogeneity in Discrete Choice Experiments: An Application to Public Preferences for Prenatal Screening Patient. 2020 Apr;13(2):211-223. doi: 10.1007/s40271-019-00402-w..
124. Mukwikwi ER, CPineau CA, Vinet E, **Clarke AE**, Nashi E, Kalache F, Grenier LP, Bernatsky S. Retinal complications in patients with systemic lupus erythematosus treated with antimalarial drugs. *J Rheumatol* April 2020, 47 (4) 553-556.
125. Murphy J, **Xie H**, Nguyen V, Chau LW, Oanh PT, Nhu TK, O'Neil J, Goldsmith CH, Hoi NV, Ma Y, Lou H, Jones W, Minas H. Is supported self-management for depression effective for adults in community-based settings in Vietnam?: a modified stepped-wedge cluster randomized controlled trial. *Int J Ment Health Syst*. 2020; 14: 8. Published online 2020 Feb 12.
126. Ortel TL, Meleth S, Catellier D, Crowther M, Erkan D, **Fortin PR**, Garcia D, Haywood N, Kosinski AS, Levine SR, Phillips MJ, Whitehead N. Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and meta-analysis. *Journal of Thrombosis and Haemostasis*. doi: 10.1111/jth.14936. [Epub ahead of print]
127. Ostermann J, Brown DS, van Til JA, **Bansback N**, Légaré F, **Marshall DA**, Bewtra M. Support tools for preference-sensitive decisions in healthcare: where are we? where do we go? how do we get there? *Patient*. 2019 Oct;12(5):439-443. doi: 10.1007/s40271-019-00372-z.
128. Palmer D, Cooper D, Emery CA, Batt M, Engebrestsen L, Scammell B, Soligard, T, Steffen K, **Whittaker JL**, Budgett R. A cross-sectional epidemiological study of Olympic-career sports injuries in 3,357 Olympians: The retired Olympian musculoskeletal health study (ROMHS). 2020 (Accepted by *Br J Sport Med* 2020-04-27)
129. Papp K, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, Bressler B, Gooderham M, Ho V, **Jamal S**, Pope JE, Steinhart A, Vinh D, Wade J. Vaccination guidelines for patients with immune-mediated disorders taking immunosuppressive therapies: executive summary. *J Rheumatol*. 2019 Jul;46(7):751-754. doi: 10.3899/jrheum.180784. Epub 2019 Feb 1.

130. Park JY, **Howren A, Zusman EZ, Esdaile JM, De Vera MA**. The incidence of depression and anxiety in patients with ankylosing spondylitis: A systematic review and meta-analysis. Accepted BMC Rheumatology. 2019 Dec 23.
131. Piesik P, Han C, de Gannes G, **Dutz J**. Corticosteroid application prior to nickel exposure prevents contact dermatitis in sensitized individuals. *Contact Dermatitis*. 2020 Mar;82(3):170-173. doi: 10.1111/cod.13416. Epub 2019 Dec 13.
132. Petkovic J, Riddle A, Akl EA, Khabisa J, Lytvyn L, Atwere P, Campbell P, Chalkidou K, Chang SM, Crowe S, Dans L, Jardali FE, Gherzi D, Graham ID, Grant S, Greer-Smith R, Guise JM, **Hazlewood G**, et al. Protocol for the development of guidance for stakeholder engagement in health and healthcare guideline development and implementation. *Syst Rev*. 2020 Feb 1;9(1):21. doi: 10.1186/s13643-020-1272-5.
133. Petri M, Goldman DW, Alarcón GS, Gordon C, Merrill JT, **Fortin PR**, Bruce IN, Isenberg D, Wallace D, Nived O, Ramsey-Goldman R, Bae SC, Hanly JG, Sanchez-Guerrero J, **Clarke AE**, Aranow C, Manzi S, Urowitz M, Gladman DD, Kalunian K, Werth VP, Zoma A, Bernatsky S, Khamashta M, Jacobsen S, Buyon JP, Dooley MA, van Vollenhoven R, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim S, Inanç M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Magder LS. A comparison of 2019 EULAR/ACR SLE classification criteria with two sets of earlier SLE classification criteria. *Arthritis Care Res (Hoboken)*. 2020 May 20. doi: 10.1002/acr.24263. [Epub ahead of print]
134. Pokharel G, Deardon R, **Barnabe C**, Bykerk V, **Bartlett SJ**, Bessette L, Boire G, Hitchon CA, Keystone E, Pope J, Schieir O, Tin D, Thorne C, **Hazlewood GS**; Canadian Early Arthritis Cohort (CATCH) Investigators, Baron M, Bessette L, Boire G, Bykerk V, **Colmegna I**, Fallavollita S, Haaland D, Haraoui P, Hazlewood G, Hitchon C, Jamal S, Joshi R, Keystone E, Nair B, Panopoulos P, Penney C, Pope J, Rubin L, Thorne C, Villeneuve E, Zimmer M. Joint Estimation of remission and response for methotrexate-based DMARD options in rheumatoid arthritis: a bivariate network meta-analysis. *ACR Open Rheumatol*. 2019 Aug 8;1(8):471-479. doi: 10.1002/acr2.11052. eCollection 2019 Oct.
135. Ponzio M, **Dutz J**. Prevention of allopurinol-associated adverse cutaneous drug reactions in high-risk patient groups in Canada. *CMAJ*. 2020 Feb 18;192(7):E168. doi: 10.1503/cmaj.74133. Prevention of allopurinol-associated adverse cutaneous drug reactions in high-risk patient groups in Canada.
136. Puyade M, Maltez N, Lansiaux P, Pugnet G, Roblot P, **Colmegna I, Hudson M, Farge D**. Health-related quality of life in systemic sclerosis before and after autologous haematopoietic stem cell transplant-a systematic review. *Rheumatology (Oxford)*. 2020 Apr 1;59(4):779-789.
137. Qendro T, de la Torre ML, Panopolis P, Hazel E, Ward BJ, **Colmegna I, Hudson M**. Suboptimal immunization coverage among Canadian rheumatology patients in routine clinical care. *J Rheumatol*. May 2020, 47 (5) 770-778.

138. Radin M, Sciascia S, Erkan D, Pengo V, Tektonidou MG, Ugarte A, Meroni P, Ji L, Belmont HM, Cohen H, Ramires de Jesús G, Branch DW, **Fortin PR**, et al; APS ACTION. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. *Semin Arthritis Rheum*. 2019 Dec;49(3):464-468. doi: 10.1016/j.semarthrit.2019.04.009. Epub 2019 May 2.
139. Ramiro S, Landewe R, van der Heijde D, Sepriano A, FitzGerald O, Ostergaard M, Homik J, Elkayam O, Thorne JC, Larche M, Ferracioli G, Backhaus M, Boire G, Combe B, Saraux A, Dougados M, Rossini M, Govoni M, Cantagrel A, Allaart C, **Barnabe C**, Bingham C, Tak PP, van Schaardenburg D, Hammer H, Dadashova R, Hutchings E, Paschke J, Maksymowych W. Is Treat-to-Target really working in rheumatoid arthritis? A longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). *Ann Rheum Dis*. 2020 Apr;79(4):453-459. doi: 10.1136/annrheumdis-2019-216819. [Epub ahead of print].
140. Raparelli V, Elharram M, Moura CS, **Abrahamowicz M**, Bernatsky S, Behloul H, Pilote L. Sex differences in cardiovascular effectiveness of newer glucose-lowering drugs added to metformin in Type 2 diabetes mellitus. *J Am Heart Assoc*. 2020 Jan 7;9(1):e012940. doi: 10.1161/JAHA.119.012940. Epub 2020 Jan 4.
141. **Rebić N, Sayre EC, Zusman EZ**, Amiri N, Baldwin C, **De Vera MA**. Perinatal use and discontinuation of disease-modifying anti-rheumatic drugs and biologics in women with rheumatoid arthritis: a cohort study. *Rheumatology (Oxford)*. 2020 Jul 1;59(7):1514-1521. doi: 10.1093/rheumatology/kez478.
142. Rezaei E, Hogan D, Trost B, Kusalik AJ, Boire G, Cabral DA, Campillo S, Chédeville G, Chetaille AL, Dancey P, Duffy C, Watanabe Duffy K, Gordon J, Guzman J, Houghton K, Huber AM, Jurencak R, Lang B, Morishita K, Oen KG, Petty RE, Ramsey SE, Scuccimarri R, Spiegel L, Stringer E, Taylor-Gjevre RM, Tse SML, Tucker LB, Turvey SE, Tupper S, Yeung RSM, **Benseler S**, Ellsworth J, Guillet C, Karananayake C, Muhajarine N, Roth J, Schneider R, Rosenberg AM. Clinical and associated inflammatory biomarker features predictive of short-term outcomes in non-systemic juvenile idiopathic arthritis. *Rheumatology (Oxford)*. 2020 Jan 9. pii: kez615. doi: 10.1093/rheumatology/kez615. [Epub ahead of print].
143. Ripamonti E, Azoulay L, **Abrahamowicz M**, Platt RW, Suissa S. Pioglitazone and bladder cancer: improving research methods. *Diabet Med*. 2020 May;37(5):898-899. doi: 10.1111/dme.14248. Epub 2020 Feb 6.
144. Roberts J, Ennis D, **Hudson M**, Ye C, Saltman A, Rottapel R, Pope J, Hoa S, Tisseverasinghe A, Fifi-Mah A, Maltez N, **Jamal S**. Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort. *Autoimmun Rev*. 2020 Aug;19(8):102595. doi: 10.1016/j.autrev.2020.102595. Epub 2020 Jun 11.

145. Rumsey DG, Guzman J, Rosenberg AM, Huber AM, Scuccimarri R, Shiff NJ, Bruns A, Feldman BM, Eurich DT, **Benseler SJ**. Research in arthritis in Canadian children emphasizing outcomes investigators. Worse quality of life, function, and pain in children with enthesitis, irrespective of their juvenile arthritis category. *Arthritis Care Res (Hoboken)*. 2020 Mar;72(3):441-446. doi: 10.1002/acr.23844.
146. Saad El Din K, Loree JM, **Sayre EC**, Gill S, Brown CJ, Dau H, **De Vera MA**. Trends in the epidemiology of young-onset colorectal cancer: a worldwide systematic review. *BMC Cancer*. 2020 Apr 6;20(1):288. doi: 10.1186/s12885-020-06766-9.
147. Salbach NM, Barclay R, Webber SC, **Jones CA**, Mayo NE, Lix LM, Ripat J, Grant T, van Ineveld C, Chilibeck PD. A theory-based, task-oriented, outdoor walking programme for older adults with difficulty walking outdoors: protocol for the Getting Older Adults Outdoors (GO-OUT) randomised controlled trial. *BMJ Open*. 2019 Apr 20;9(4):e029393. doi: 10.1136/bmjopen-2019-029393.
148. **Salmasi S, Sayre EC, Aviña-Zubieta JA, Esdaile JM, De Vera MA**. Adherence to antimalarial therapy and risk of type 2 diabetes mellitus among patients with systemic lupus erythematosus: a population-based study. *Arthritis Care Res*. 2020 Jan 21. doi: 10.1002/acr.24147. [Epub ahead of print].
149. Saper VE, Chen G, Deutsch GH, Guillerman RP, Birgmeier J, Jagadeesh K, Canna S, Schulert G, Deterding R, Xu J, Leung AN, Bouzoubaa L, Abulaban K, Baszis K, Behrens EM, Birmingham J, Casey A, Cidon M, Cron RQ, De A, De Benedetti F, **Benseler SJ**, et al & Childhood Arthritis and Rheumatology Research Alliance Registry Investigators. Emergent high fatality lung disease in systemic juvenile arthritis. *Ann Rheum Dis*. 2019 Dec;78(12):1722-1731. doi: 10.1136/annrheumdis-2019-216040. Epub 2019 Sep 27.
150. Seet T, **De Vera MA, Howren A**, Chan D, Albon S. Medication adherence teaching activity for first year pharmacy students in a Canadian university: description and evaluation. *Curr Pharm Teach Learn*. 2020 Jan;12(1):65-73. doi: 10.1016/j.cptl.2019.10.013. Epub 2019 Nov 19.
151. Sepriano A, Ramiro S, FitzGerald O, Østergaard M, Homik J, van der Heijde D, Elkayam O, Thorne JC, Larché MJ, Ferraccioli G, Backhaus M, Burmester GR, Boire G, Combe B, Schaeffer T, Saraux A, Dougados M, Rossini M, Govoni M, Sinigaglia L, Cantagrel A, **Barnabe C**, Bingham CO 3rd, Tak PP, van Schaardenburg D, Berner Hammer H, Paschke J, Dadashova R, Hutchings E, Landewé R, Maksymowych WP. Adherence to treat-to-target management in rheumatoid arthritis and associated factors: data from the International RA BIODAM Cohort. *J Rheumatol*. 2020;47(6):809-819. pii: jrheum.190303. doi: 10.3899/jrheum.190303. [Epub ahead of print].
152. Stok KS, Burghardt AJ, Boutroy S, Peters MPH, Manske SL, Vilayphiou N, van den Bergh J, Geusens P, Li X, Marotte H, van Rietbergen B, Boyd SD, **Barnabe C**, for the SPECTRA Collaboration. Consensus approach for 3D joint space width of metacarpophalangeal joints of rheumatoid arthritis patients using high-resolution peripheral quantitative computed tomography. *Quant Imaging Med Surg*. 2020 Feb;10(2):314-325. doi: 10.21037/qims.2019.12.11.

153. Tagimacruz MA, Bischak D, **Marshall DA**. Alternative care providers in rheumatoid arthritis patient care: A queueing and simulation analysis. *Health Systems*. June 14, 2020, published online.
154. **Tam J, Lacaille D**, Liu-Ambrose T, Shaw C, **Xie H, Backman CL, Esdaile JM**, Miller K, Petrella R, **Li LC**. Effectiveness of an online self-management tool, OPERAS (an On-demand Program to Empower Active Self-management), for people with rheumatoid arthritis: a research protocol. *BMC Trials*. 2019;20(1):712.
155. Tamblyn R, **Abrahamowicz M**, Buckeridge DL, Bustillo M, Forster AJ, Girard N, Habib B, Hanley J, Huang A, Kurteva S, Lee TC, Meguerditchian AN, Moraga T, Motulsky A, Petrella L, Weir DL, Winslade N. Effect of an Electronic Medication Reconciliation Intervention on Adverse Drug Events: A Cluster Randomized Trial. *JAMA Netw Open*. 2019 Sep 4;2(9):e1910756. doi: 10.1001/jamanetworkopen.2019.10756.
156. Targownik L, Benchimol E, Berntein C, Singh H, Lix L, Tennakoon A, Leung S, **Aviña-Zubieta JA**, Coward S, Jones J, Kaplan G, Murthy SK, Nguyen G, Pena-Sanchez JN. Upfront combination therapy, compared with monotherapy, for patients not previously treated with a biologic agent associates with reduced risk of inflammatory bowel disease-related complications in a population-based cohort study. *Clinical Gastroenterology and Hepatology*. 2019;17:1788–1798.
157. Targownik LE, Kaplan GG, Witt J, Bernstein CN, Singh H, Tennakoon A, **Aviña-Zubieta JA**, Coward SB, Jones J, Kuenzig ME, Murthy SK, Nguyen GC, Peña-Sanchez JN, Benchimol EI. Longitudinal trends in the direct costs and health care utilization ascribable to inflammatory bowel disease in the biologic era: results from a Canadian population based analysis. *Am J Gastroenterol*. 2020 Jan;115(1):128-137. doi: 10.14309/ajg.0000000000000503.
158. Targownik L, Benchimol E, Bernstein E, Singh H, Aruni T, **Aviña-Zubieta JA**, Coward S, Jones J, Kaplan GG, Kuenzig E, Murthy S, Nguyen G, Pena Sanchez J.. Combined biologic and Immunomodulatory therapy is superior to monotherapy for decreasing the risk of inflammatory bowel disease-related complication. *Crohn's Colitis*. 2020 Jul 10;jjaa050. doi: 10.1093/ecco-jcc/jjaa050. Online ahead of print.
159. Tatangelo M, Tomlinson G, Paterson JM, Ahluwalia V, Kopp A, Gomes T, **Bansback N**, Bombardier C. Association of patient, prescriber, and region with the initiation of first prescription of biologic disease-modifying antirheumatic drug among older patients with rheumatoid arthritis and identical health insurance coverage. *JAMA Netw Open*. 2019 Dec 2;2(12):e1917053. doi: 10.1001/jamanetworkopen.2019.17053.
160. Tessandier N, Melki I, Cloutier N, Allaeyes I, Miszta A, Tan S, Milasan A, Michel S, Benmoussa A, Lévesque T, Côté F, McKenzie SE, Gilbert C, Provost P, Brisson AR, Wolberg AS, **Fortin PR**, Martel C, Boilard E. Platelets disseminate extracellular vesicles in lymph in rheumatoid arthritis. *Arterioscler Thromb Vasc Biol*. 2020 Apr;40(4):929-942. doi: 10.1161/ATVBAHA.119.313698. Epub 2020 Feb 27.

161. Thombs BD, Aguila K, Dyas L, Carrier ME, Fedoruk C, Horwood L, Cañedo-Ayala M, Sauvé M, Kwakkenbos L, Malcarne VL, El-Baalbaki G, Peláez S, Connolly K, **Hudson M**, Platt RW; SPIN-SSLED Support Group Advisory Team. Protocol for a partially nested randomized controlled trial to evaluate the effectiveness of the Scleroderma Patient-centered Intervention Network Support Group Leader Education (SPIN-SSLED) Program. *Trials*. 2019 Dec 12;20(1):717. doi: 10.1186/s13063-019-3747-z.
162. Thombs BD, Dyas L, Pépin M, Aguila K, Carrier ME, Tao L, Harb S, Malcarne VL, El-Baalbaki G, Peláez S, Sauve M, **Hudson M**, Platt RW; SPIN-SSLED Patient Advisory Team. Scleroderma Patient-centered Intervention Network-Scleroderma Support group Leader Education (SPIN-SSLED) program: non-randomised feasibility trial. *BMJ Open*. 2019 Nov 11;9(11):e029935. doi: 10.1136/bmjopen-2019-029935.
163. **Truong L**, Mosewich A, Miciak M, **Le CY**, Holt C, **Whittaker JL**. Psychological, social and contextual factors across recovery stages following a sport-related knee injury: A scoping review. *Br J Sports Med Online First*: February 14. doi:10.1136/bjsports-2019-101206.
164. **Tsao NW**, Hanley GE, Lynd LD, Amiri N, **De Vera MA**. Risk of congenital anomalies in infants born to women with autoimmune disease using biologics before or during pregnancy: a population-based cohort study. *Clin Exp Rheumatol*. 2019 Nov-Dec;37(6):976-982.
165. **Truong L**, Mosewich A, Miciak M, **Le CY**, Holt C, **Whittaker JL**. Psychological, social and contextual factors across recovery stages following a sport-related knee injury: A scoping review. *Br J Sports Med*. 2020 Feb 14. pii: bjsports-2019-101206. doi: 10.1136/bjsports-2019-101206. [Epub ahead of print].
166. Urowitz MB, Gladman DD, Farewell V, Su J, Romero-Diaz J, Bae SC, **Fortin PR**, Sanchez-Guerrero J, **Clarke AE**, Bernatsky S, Gordon C, Hanly JG, Wallace DJ, Isenberg D, Rahman A, Merrill J, Ginzler E, Alarcón GS, Chatham WW, Petri M, Bruce IN, Khamashta M, Aranow C, Dooley M, Manzi S, Ramsey-Goldman R, Nived O, Jönsen A, Steinsson K, Zoma A, Ruiz-Irastorza G, Lim S, Kalunian KC, İnanç M, van Vollenhoven R, Ramos-Casals M, Kamen DL, Jacobsen S, Peschken C, Askanase A, Stoll T. Accrual of atherosclerotic vascular events in a multicentre inception SLE cohort. *Arthritis Rheumatol*. 2020 Jun 9. [Epub ahead of print] Pub
167. Valerio V, Bazan M, Wang M, Mazer B, Hazel EM, Pineau C, Bernatsky S, **Colmegna I**. Perceptions about interventions to enhance influenza vaccine uptake differ between vaccinated and unvaccinated RA/JIA patients. *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 288.
168. Vallerand IA, Lewinson RT, Parsons LM, Lowerison MW, Patten SB, Barnabe C. Depression as a risk factor for the development of psoriasis: a retrospective cohort study in the UK. *Br J Dermatol*. 2020 Apr 30. doi: 10.1111/bjd.19160. Online ahead of print.

169. Wallace ZS, Naden RP, Chari S, **Choi HK**, Della-Torre E, Dicaire JF, Hart PA, Inoue D, Kawano M, Khosroshahi A, Lanzillotta M, Okazaki K, Perugino CA, Sharma A, Saeki T, Schleinitz N, Takahashi N, Umehara H, Zen Y, Stone JH, **Carruthers M**; Members of the ACR/EULAR IgG4-RD Classification Criteria Working Group. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. *Ann Rheum Dis*. 2020 Jan;79(1):77-87. doi: 10.1136/annrheumdis-2019-216561. Epub 2019 Dec 3. Review.
170. Wallace ZS, Naden RP, Chari S, **Choi H**, Della-Torre E, Dicaire JF, Hart PA, Inoue D, Kawano M, Khosroshahi A, Kubota K, Lanzillotta M, Okazaki K, Perugino CA, Sharma A, Saeki T, Sekiguchi H, Schleinitz N, Stone JR, Takahashi N, Umehara H, Webster G, Zen Y, Stone JH; **Carruthers M**; American College of Rheumatology/European League Against Rheumatism IgG4-Related Disease Classification Criteria Working Group. The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. *Arthritis Rheumatol*. 2020 Jan;72(1):7-19. doi: 10.1002/art.41120. Epub 2019 Dec 2.
171. Wallace ZS, Harkness T, Fu X, Stone JH, **Choi HK**, Walensky RP. Treatment delays associated with prior authorization for infusible medications: a cohort study. *Arthritis Care Res (Hoboken)*. 2019 Sep 10. doi: 10.1002/acr.24062. [Epub ahead of print].
172. Wallace ZS, Harkness T, Blumenthal KG, **Choi HK**, Stone JH, Walensky RP. Increasing Operational Capacity and Reducing Costs of Rituximab Administration: A Costing Analysis. *ACR Open Rheumatol*. 2020 May;2(5):261-268. doi: 10.1002/acr2.11133. Epub 2020 Apr 21.
173. Wang Y, Beauchamp ME, **Abrahamowicz M**. Nonlinear and time-dependent effects of sparsely measured continuous time-varying covariates in time-to-event analysis. *Biom J*. 2020 Mar;62(2):492-515. doi: 10.1002/bimj.201900042. Epub 2020 Feb 5.
174. Wei J, Lane NE, Bolster MB, Dubreuil M, Zeng C, Misra D, **Lu N, Choi HK**, Lei G, Zhang Y. Association of tramadol use with risk of hip fracture. *J Bone Miner Res*. 2020 Apr;35(4):631-640. doi: 10.1002/jbmr.3935. Epub 2020 Feb 5.
175. Wei J, Wood MJ, Dubreuil M, Tomasson G, LaRochelle MR, Zeng C, Lu N, Lin J, **Choi HK**, Lei G, Zhang Y. Association of tramadol with risk of myocardial infarction among patients with osteoarthritis. *Osteoarthritis Cartilage*. 2020 Feb;28(2):137-145. doi: 10.1016/j.joca.2019.10.001. Epub 2019 Oct 16.
176. Weir DL, Motulsky A, **Abrahamowicz M**, Lee TC, Morgan S, Buckeridge DL, Tamblyn R. Challenges at Care Transitions: Failure to Follow Medication Changes Made at Hospital Discharge. *Am J Med*. 2019 Oct;132(10):1216-1224.e5. doi: 10.1016/j.amjmed.2019.05.003. Epub 2019 May 28.
177. **Whittaker JL**, Roos EM. Infographic: Risk profile for sport-related post-traumatic knee osteoarthritis. *Br J Sports Medicine*. *Br J Sports Med*. 2020 Mar;54(6):362-363. doi: 10.1136/bjsports-2019-100877. Epub 2019 Aug 3.

178. **Whittaker JL**, Chan M, Pan B, Hassan I, DeFreitas T, Hui C, Macedo L, Otto D (2020). Towards improving the identification of Anterior Cruciate Ligament tears in primary care. 2019 BMC Musculoskel Dis. 21(1):252 doi: 10.1186/s12891-020-03237-x.
179. **Whittaker JL**. Avoiding the Knife: Preventing sports injuries and osteoarthritis, European Congress of Rheumatology Frankfurt, Germany, June 3-6, 2020 (Conference switched to e-Conference due to COVID-19) (Plenary).
180. Wu Y, Levis B, Riehm KE, Saadat N, Levis AW, Azar M, Rice DB, Boruff J, Cuijpers P, Gilbody S, Ioannidis JPA, Kloda LA, McMillan D, Patten SB, Shrier I, Ziegelstein RC, Akena DH, Arroll B, Ayalon L, Baradaran HR, Baron M, Bombardier CH, Butterworth P, Carter G, Chagas MH, Chan JCN, Cholera R, Conwell Y, de Man-van Ginkel JM, Fann JR, Fischer FH, Fung D, Gelaye B, Goodyear-Smith F, Greeno CG, Hall BJ, Harrison PA, Härter M, Hegerl U, Hides L, Hobfoll SE, **Hudson M**, Thombs BD, et al. Equivalency of the diagnostic accuracy of the PHQ-8 and PHQ-9: a systematic review and individual participant data meta-analysis. Psychol Med. 2020 Jun;50(8):1368-1380. doi: 10.1017/S0033291719001314. Epub 2019 Jul 12.
181. Yamamoto SS, Yacyshyn E, Jhangri GS, Chopra A, Parmar D, **Jones CA**. Household air pollution and arthritis in low- and middle-income countries: Cross-sectional evidence from the World Health Organization's Study on global ageing and adult health. PLoS One 2019; 14(12): e0226738. <https://doi.org/10.1371/journal.pone.0226738>.
182. Yokose C, **Leo N, Xie H, Li G, Zheng Y, McCormick N, Rai S, Aviña-Zubieta JA, Choi HK**. Heart disease and the risk of allopurinol-associated severe cutaneous adverse reactions: a general-population-based cohort study. CMAJ. 2019 Sep 30;191(39):E1070-E1077. doi: 10.1503/cmaj.190339.
183. Yokose C, Dalbeth N, Wei J, Nicolaou S, Simeone FJ, Baumgartner S, Fung M, Zhang Y, **Choi HK**. Radiologic evidence of symmetric and polyarticular monosodium urate crystal deposition in gout - A cluster pattern analysis of dual-energy CT. Semin Arthritis Rheum. 2020 Feb;50(1):54-58. doi: 10.1016/j.semarthrit.2019.07.002. Epub 2019 Jul 11.
184. Yokose C, **Lu L, McCormick N**, Choi J, Zhang H, **Choi H**. Fast food habits and serum urate change in young adults: 15-year prospective analysis. Ann Rheum Dis, volume 79, supplement 1, year 2020, page 1257.
185. Yoshida K, Lin TC, Wei M, Malspeis S, Chu SH, Camargo CA, Raby BA, **Choi HK**, Tedeschi SK, Barbaiya M, Lu B, Costenbader KH, Karlson EW, Sparks JA. The roles of post-diagnosis accumulation of morbidities and lifestyle changes on excess total and cause-specific mortality risk in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2019 Dec 7. doi: 10.1002/acr.24120. [Epub ahead of print].
186. Yuan C, Hedeker D, Mermelstein R, **Xie H**. A tractable method to account for high-dimensional nonignorable missing data in intensive longitudinal data. Statistics in Medicine. 2020; 1– 17.

187. Zhang Y, Coello PA, Guyatt GH, Yepes-Nuñez JJ, Akl EA, **Hazlewood G**, Pardo-Hernandez H, Etxeandia-Ikobaltzeta I, Qaseem A, Williams JW Jr, Tugwell P, Flottorp S, Chang Y, Zhang Y, Mustafa RA, Rojas MX, Xie F, Schünemann HJ. GRADE guidelines: 20. Assessing the certainty of evidence in the importance of outcomes or values and preferences-inconsistency, imprecision, and other domains. *J Clin Epidemiol*. 2019 Jul;111:83-93.
188. Zhang T, Lee TK, Lui H, **Dutz J**, Dawes M, Lee A, Kalia S. Health insurance claim- and prescription record-based algorithms as a population-based method for eczema ascertainment. *J Eur Acad Dermatol Venereol*. 2020 Feb 26. doi: 10.1111/jdv.16315. Online ahead of print.
189. Zhao N, Smargiassi A, **Hudson M**, Fritzler MJ, Bernatsky S. Investigating associations between anti-nuclear antibody positivity and combined long-term exposures to NO₂, O₃, and PM_{2.5} using a Bayesian kernel machine regression approach. *Environ Int*. 2020 Mar;136:105472.
190. Zhao EJ, **Carruthers MN**, Li CH, Mattman A, Chen LYC. Conditions associated with polyclonal hypergammaglobulinemia in the IgG4-related disease era: a retrospective study from a hematology tertiary care center. *Haematologica*. 2020 Mar;105(3):e121-e123.
191. Zhao K, Oualkacha K, Lakhal-Chaieb L, Labbe A, Klein K, Ciampi A, **Hudson M**, **Colmegna I**, Pastinen T, Zhang T, Daley D, Greenwood CMT. A novel statistical method for modeling covariate effects in bisulfite sequencing derived measures of DNA methylation. *Biometrics*. 2020 May 21. doi: 10.1111/biom.13307. Online ahead of print.
192. Zheng B, Nevskaya T, Baxter CA, Ramey DR, Pope JE, Baron M, **Fortin PR**; Canadian Scleroderma Research Group . Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity. *Rheumatology (Oxford)*. 2020 Feb 1;59(2):398-406.
193. Zheng B, **Hudson M**, Wang M, Baron M; Canadian Scleroderma Research Group including **Fortin PR**. Immunosuppressive treatment in diffuse cutaneous systemic sclerosis is associated with an improved composite response index (CRISS). *Arthritis Res Ther*. 2020 Jun 5;22(1):132.
194. **Zusman EZ**, **Sayre EC**, **Aviña-Zubieta JA**, **De Vera MA**. Patterns of medication use before, during and after pregnancy in women with systemic lupus erythematosus: a population-based cohort study. *Lupus*. Sep;28(10):1205-1213.

ABSTRACTS

1. Adrian-Hamazaki A, **Li LY, Lu N, Zheng Y, Lacaille D, Esdaile J, Choi H, Avina-Zubieta JA**. The risk and trend of venous thromboembolism in patients with rheumatoid arthritis: a general population-based study. *J Rheumatol*. 2020;47(7):1082.
2. Aguir M, Munro S, Bursch T, Kaal J, Laba TL, **Bansback N, Harrison M**. Understanding the preferences of people with scleroderma regarding stem cell transplant: a patient-oriented approach to inform design of early phase clinical studies. *J Rheumatol*. 2020;47(7):1134-35.
3. Amiable N, Longchamps M-P, Ouellet L, Julien A-S, Rollet-Labelle E, Ikic A, Albert A, **Michou L**, Bessette L, Tessier PA, Pelletier M, **Fortin PR**. Les cytokines plasmatiques : un nouvel outil de classification des patients avec des Maladies Rhumatismales Autoimmunes Systémiques (MRAS). Poster presentation at the Journées de la recherche du CHU de Québec - Université Laval, Québec, Canada, May 30-31, 2019.
4. Amlani A, Tarnopololsky M, Brady L, Schmeling H, Swain M, Stingl C, Reed A, **Hudson M**, Fritzler M. Anti-valosin-containing protein (VCP/p97) autoantibodies as a diagnostic biomarker in inclusion body myositis. *J Rheumatol*. 2020;47(7):1118.
5. Amlani A, **Choi M, Clarke A, Barber C**, Jung M, Fritzler M. Anti-NT5c1A Autoantibodies in systemic lupus erythematosus. *J Rheumatol*. 2020;47(7):1118-19.
6. Amlani A, **Choi M**, Tarnopololsky M, Brady L, **Clarke A**, De La Torre I, Schmeling H, Stingl C, Reed A. Evaluation of Anti-NT5c1A autoantibodies as a diagnostic biomarker in juvenile dermatomyositis. *J Rheumatol*. 2020;47(7):1118.
7. Amlani A, Tarnopololsky M, Brady L, Schmeling H, Swain M, Stingl C, Hudson M, Fritzler M. Anti-Valosin-Containing Protein (VCP/p97) autoantibodies as a diagnostic biomarker in inclusion body myositis. *J Rheumatol*. 2020;47(7):1118.
8. Anderson KM, Schieir O, Valois MF, **Bartlett SJ**, Bessette L, Boire G, **Hazlewood G**, Hitchon C, Keystone E, Pope J, Tin D, Thorne C, Bykerk V and Canadian Early Arthritis Cohort (CATCVH) Investigators. Duration of oral corticosteroid therapy does not change with the addition of a parenteral injection: results from a real-world Canadian early RA cohort. *Arthritis Rheum*. 71(Suppl 10):2411-2414.
9. Anderson N, Schieir O, Valois MF, Boire G, Pope J, **Hazlewood G**, Bessette L, Hitchon C, Tin D, Thorne C, Keystone E, Bykerk V, **Bartlett SJ**, and Canadian Early Arthritis Cohort (CATCH) Investigators. Major stressors in the year prior to diagnosis affects RA characteristics at presentation and 1 year. *Arthritis Rheum*. 71(Suppl 10):3990-3992.
10. Andersen N, Schieir O, Valois MF, Boire G, Pope J, **Hazlewood G**, Bessette L, Hitchon C, Tin D, Thorne C, Keystone E, Bykerk V, **Bartlett SJ**, on behalf of CATCH Investigators. Major stressors in the year prior to RA diagnosis: Impact on patient-reported outcomes one year later. *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 165.

11. Anderson K, Schieir O, Valois MF, Boire G, Pope J, **Hazlewood G**, Bessette L, Hitchon C, Tin D, Thorne C, Keystone E, Bykerk V, **Bartlett S**, CATCH Canadian Early Arthritis Cohort Investigators. Major stressors in the year prior to diagnosis affects RA characteristics at presentation and 1 year. *J Rheumatol*. 2020;47(7):1083.
12. Anderson K, Schieir O, Valois MF, **Bartlett S**, Bessette L, Boire G, **Hazlewood G**, Hitchon C, Keystone E, Pope J, Tin D, Thorne C, Bykerk V, CATCH Canadian Early Arthritis Cohort Investigators. Does concomitant use of multiple steroid routes in Early RA facilitate oral steroid discontinuation? Results from a real-world Canadian cohort. *J Rheumatol*. 2020;47(7):1133.
13. **Atiquzzaman M**, Darim M, **Kopec J**, Wong H, **De Vera M**, **Anis A**. Using external data to estimate omitted variables in observational data: a plasmode simulation study investigating the relationship between osteoarthritis and cardiovascular diseases to compare alternative approaches in imputing the body mass index variable. *Arthritis Rheum*. 2019;71(Suppl 10):4267-4269.
14. Aydin S, Rahman P, **Chan J**, Wang CA, Chen YH, Tian H, Leclerc P, Parent S. Real-World effectiveness of secukinumab in the treatment of ankylosing spondylitis in Canada: retrospective analysis using data from the Patient Support Program. *J Rheumatol*. 2020;47(7):1040.
15. **Barber C**, Mosher D, **Hazlewood G**, MacMullan P, **Barnabe C**, **Bohm V**, Rankin J, Homik J, **English K**, **Tsui K**, Pan B, Stevenson M, Sandhu N, Emrick A, Martin L, Durand C, Jung M, **Lacaille D**. Testing rheumatoid arthritis performance measures to optimize treat to target strategies. *Arthritis Rheum*. 2019;71(Suppl 10):2081-2082.
16. **Barber C**, Shiff N, **Barnabe C**, **Benseler S**, Chin R, Johnson N, Luca N, Miettunen P, Twilt M, Veeramreddy D, Schmeling H. Are we meeting benchmarks for wait times for pediatric rheumatology care for juvenile idiopathic arthritis (JIA)? *Arthritis Rheum*. 71(Suppl 10):2080-2081.
17. **Barber CEH**, Twilt M, Pham T, Currie G, **Benseler S**, Yeung R, Batthish M, Blanchette N, Guzman J, Lang B, LeBlanc C, Levy D, O'Brien C, Schmeling H, Soon G, Spiegel L, Whitney K, **Marshall D**. A Canadian evaluation framework for quality improvement in childhood arthritis: key performance indicators of the process of care. *J Rheumatol*. 2020;47(7):1034.
18. Baril-Dionne A, Landon-Cardinal O, Meyer A, Bourre-Tessier J, Troyanov Y, Mansour AM, Zarka F, Makhzoum JP, Nehme J, Rich E, Goulet JR, Grodzicky T, Richard I, **Hudson M**, Leclair V, Targoff I, Satoh M, Fritzler M, Senecal JL. Single-specificity anti-SMN autoantibodies are associated with a novel scleromyositis overlap syndrome. *Arthritis Rheum*. 71(Suppl 10):652-53.
19. **Bartlett SJ**, Schieir O, Valois MF, Pope J, Bessette L, Hitchon C, Thorne C, Tin D, **Hazlewood G**, Boire G, Keystone E, Bykerk V and Canadian Early Arthritis Cohort (CATCH) Investigators. Obesity is a robust predictor of persistent high fatigue at 1 year in women and men with early rheumatoid arthritis. *Arthritis Rheum*. 71(Suppl 10):782-784.

20. **Bartlett SJ**, Schieir O, Valois MF, Hitchon C, Bessette L, **Hazlewood G**, Thorne C, Pope J, Boire G, Tin D, Keystone E, Bykerk V and Canadian Early Arthritis Cohort (CATCH) Investigators. When will I get past this exhaustion? Predictors of improved fatigue in the first year of RA. *Arthritis Rheum.* 71(Suppl 10):785-787.
21. **Bartlett S**, Schieir O, Valois MF, Hitchon C, Bessette L, **Hazlewood G**, Tin D, Thorne C, Pope J, Boire G, Keystone E, Bykerk V, CATCH Canadian Early Arthritis Investigators. When will I get past this exhaustion? Patterns and risk factors for improved fatigue in the first year of rheumatoid arthritis. *J Rheumatol.* 2020;47(7):1132.
22. **Bartlett S**, Schieir O, Pope J, Hitchon C, **Hazlewood G**, Boire G, Bessette L, Tin D, Thorne C, Keystone E, Bykerk V, CATCH Canadian Early Arthritis Investigators. Predictors of persistent fatigue differ in men and women with early rheumatoid arthritis in the first year. *J Rheumatol.* 2020;47(7):1133.
23. **Bartlett S**, Bingham C, van Vollenhoven R, Murray C, Gruben D, Hsu MA, Gold D, Cella D. Associations among fatigue, vitality, sleep, and HRQL in patients with rheumatoid arthritis: data from Phase 3 Trials of Tofacitinib. *J Rheumatol.* 2020;47(7):1134.
24. Becker Y, Julien A-S, **Godbout A**, Boilard E, **Fortin PR**. Antibodies targeting mitochondrial antigens are associated with reduced thrombotic events In APS. *Arthritis Rheum.* 71(Suppl 10):173-175.
25. Benson LC, Raisanen AM, Whittaker JL, Emery CA. A wearables-based lower limb asymmetry metric to monitor rehabilitation. Canadian Bone and Joint Conference, Virtual (Zoom®), June 13, 2020.
26. Bernatsky S, Ramsey-Goldman R, Urowitz M, Hanly J, Gordon C, Petri M, Ginzler EM, Wallace DJ, Bae SC, Romero-Diaz J, Dooley MA, Peschken C, Isenberg DA, Rahman A, Manzi S, Jacobsen S, Lim SS, van Vollenhoven RF, Nived O, Kamen D, Aranow C, **Fortin P**, **Clarke AE** et al. Cancer risk in a large inception SLE cohort: effects of age, smoking and medications. *Arthritis Rheum.* 71(Suppl 10):4946-4949.
27. Boettcher T, **Jones A**, Kang S, McLeod R, Beaupre L. Effect of preoperative depression on patient reported function and pain post total joint arthroplasty (Total Hip/Knee Arthroplasty), Canadian Orthopaedic Residents' Symposium. (Montreal) June 19-22, 2019 <https://www.xcdsystem.com/coa/program/f96TB6S/index.cfm?pgid=764>.
28. Brunet S, Salat P, **Hazlewood G**, Engelke K, **Barnabe C**, Manske S. The relationship between subclinical inflammation and bone damage in patients with rheumatoid arthritis using multimodality imaging. *Arthritis Rheum.* 71(Suppl 10):2030-2032.
29. Bykerk VP, Schieir O, Valois MF, Boire G, **Hazlewood G**, Bessette L, Hitchon C, Tin D, Thorne C, Keystone E, Pope J, **Bartlett SJ** and Canadian Early Arthritis Cohort (CATCH) Investigators. Persistent and non-articular regional and widespread pain are common in early rheumatoid arthritis, impacting remission rates and reflected in patient global scores. *Arthritis Rheum.* 71(Suppl 10):748-750.

30. Bykerk V, Benson C, Vitone G, Tirpack A, **Bartlett SJ**, Bingham C. Early RA patients seen in practice who have co-existent non-articular pain have significant worsening of promis® 29 domain scores. Results from the CATCH US study. *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 1387.
31. Bykerk V, Schieir O, Valois MF, Bessette L, Boire G, **Hazlewood G**, Hitchon C, Keystone E, Tin D, Thorne C, Pope J, **Bartlett SJ**, on behalf of CATCH Investigators. Regional and widespread patterns of non-articular pain are common at RA diagnosis and contribute to poor outcomes at 12 months: A prospective study of pain patterns in Canadians with RA. *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 585.
32. Campbell E, Skeith L, Fritzler M, Jung M, **Barber C**, St. Pierre Y, **Clarke A**. Changes in antiphospholipid antibody (aPL) status over time. *J Rheumatol*. 2020; 47(7):1124.
33. **Chan J**, Stamp L, Liebergreen N, Ndukwe H, **Marra C**, Treharne G. Rheumatoid arthritis patients' perspectives on tapering of biologics: a qualitative study. *Arthritis Rheum*. 71(Suppl 10):152-53.
34. **Choi M**, **Barber M**, Fritzler M, Hanly JG, Urowitz M, St-Pierre Y, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce I, **Fortin P**, Gladman D, **Clark AE** et al. Is ANA-status at disease inception associated with long-term damage accrual and direct and indirect health care costs in the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort? *Arthritis Rheum*. 71(Suppl 10):111-114.
35. Choi J, **McCormick N**, **Marozoff S**, **De Vera M**, **Choi H**. The impact of genetically determined serum urate levels on the development of cardiovascular diseases: A systematic review and meta-analysis of Mendelian randomization studies. *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 861.
36. Cotton T, Niaki O, Zheng B, Pineau C, Fritzler M, Vinet E, **Clarke A**, Grenier LP, Kalache F, Bernatsky S. Myositis in systemic lupus erythematosus. *J Rheumatol*. 2020;47(7):1116.
37. **Da Costa D**, **Szlachetka T**, **Lacaille D**. Sleep quality in women with rheumatoid arthritis is associated with disease activity and depressive symptoms. *Arthritis Rheum*. 71(Suppl 10):787-88.
38. Davidson A, Gunay A, **Colmegna I**, **Lacaille D**, Loewen H, Meltzer M, Scuccimarri R, Mengistu Y, Bernatsky S, Hitchon C. Safety of low dose methotrexate (MTX) and tuberculosis (TB). *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 604.
39. D'Aoust J, Leclair V, Gyger G, Meyer A, Fritzler M, Landon-Cardinal O, O'Ferrall E, Karamchandani J, Ellezam B, Massie R, Sato M, Troyanov Y, **Hudson M**. Autoantibody profiles delineate three distinct subsets of scleromyositis. *Arthritis Rheum*. 71(Suppl 10):654-55.

40. Desaulniers P, Joly C, Singbo N, Wall M, Gagnon C, Mac-Way F, Rouabhia M, Brown JP, Ste-Marie LG, Morin SN, **Michou L**. Development and test of a self-administered questionnaire for adults with osteoporosis to detect familial forms of osteoporosis and/or atypical femur fractures in clinical practice. *J Rheumatol*. 2020;47(7):1065-66.
41. Deshauer S, Junek M, Masetto A, Ikic A, Smith D, Robinson D, Fritzler M, Sutton E, Gyger G, **Fortin P, Hudson M**, Baron M, Pope J, Thorne C, Khalidi N, Beattie K, Larche M. The effect of pregnancy on the progression of scleroderma. *J Rheumatol*. 2020;47(7):1086-87.
42. D'Silva K, Bolster M, Castelina F, Sharma A, Little B, Montesi S, **Choi HK**. Rituximab therapy for interstitial pneumonia with autoimmune features (IPAF): a case series of nineteen patients. *Arthritis Rheum*. 71(Suppl 10):376-78.
43. D'silva K, **Lu L**, Ogdie A, **Aviña-Zubieta JA, Choi H**. Persistent premature mortality gap in idiopathic inflammatory myopathy: A general population-based cohort study. *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 155.
44. D'silva K, Yokose C, **Lu L**, Zhang Y, **Choi H**. Sex-specific U-shaped relationship between serum urate and mortality in the United states general population. *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 10.
45. **Duncan R, De Vera M**, Law M, Conklin A, **Shojania K, Harrison M**. Evaluating the impact on access of the introduction of nurse-supported care for persons with complex rheumatic disease in British Columbia. *J Rheumatol*. 2020;47(7):1075.
46. Ellingwood L, Dehghan N, Yam J, Beaulieu M, **Chan J**, Amiri N. A case report of Takayasu Arteritis in pregnancy. *J Rheumatol*. 2020;47(7):1084.
47. **Esculier JF**, Jarrett M, Krowchuk NM, Rauscher A, Wiggermann V, Taunton JE, Wilson DR, Gatti AA, **Hunt MA**. Cartilage recovery in runners with and without knee osteoarthritis: A pilot study. *Knee*. 2019 Oct;26(5):1049-1057. doi: 10.1016/j.knee.2019.07.011. Epub 2019 Aug 18.
48. Fatima S, Schieir O, M. F. Valois MF, **Bartlett SJ**, Bessette L, Boire G, **Hazlewood G**, Hitchon C, Keystone E, Tin D, Thorne C, Bykerk V, Pope J, on behalf of CATCH Investigators. All-cause mortality in early rheumatoid arthritis predicted by health assessment questionnaire at one year. *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 588.
49. Fatima S, Schieir O, Valois MF, **Bartlett S**, Bessette L, Boire G, **Hazlewood G**, Hitchon C, Keystone E, Tin D, Thorne C, Bykerk V, Pope J. Health assessment questionnaire at one year predicts all-cause mortality in patients with early rheumatoid arthritis. *J Rheumatol*. 2020;47(7):1084.
50. **Feehan L, Li L, Lu N, Xie H**. 24-hour activity profiling in people living with arthritis: habits matter. *Arthritis Rheum*. 71(Suppl 10):4264-4266.
51. Fleischer C, Feser M, Bernis E, Striebich C, Moss LK, Kormendi V, White S, Holers M, **Harrison M**, Deane K. Preferences and insights for rheumatoid arthritis clinical prevention trial participation. *Arthritis Rheum*. 71(Suppl 10):3987-3989.

52. **Fortin PR**, Becker Y, Julien A-S, Godbout A, Boilard E. Antibodies targeting mitochondrial antigens are associated with reduced thrombotic events in the antiphospholipid syndrome (APS). Poster presentation at the 16th International Congress on Antiphospholipid Antibodies 2019, Manchester, Central UK, 17 – 20 September 2019.
53. **Fortin PR**, Longchamps M-P, Parent G, Benk-Fortin H, Julien A-S, Amiable N, Rollet-Labelle E, **Michou L**, Bessette L, Tessier PA, Pelletier M. Les cytokines plasmatiques: un nouvel outil pour prédire une mauvaise réponse au méthotrexate chez les patients atteints de polyarthrite rhumatoïde. Poster presentation at the Journées de la recherche du CHU de Québec - Université Laval, Québec, Canada, May 30-31, 2019.
54. **Fortin PR**, Becker Y, Julien A-S, Godbout A, Boilard E. Les anticorps dirigés contre l'ADN et l'ARN mitochondrial font partie du répertoire des auto-anticorps exprimés par les patients souffrant du syndrome des antiphospholipides (APS). Poster presentation at the Journées de la recherche du CHU de Québec - Université Laval, Québec, Canada, May 30-31, 2019.
55. Gańczak M, Miazgowski T, Kozybska M, Kotwas A, Korzeń M, Rudnicki B, Nogal T, Andrei CL, Ausloos M, Banach M, Brazinova A, Constantin MM, Dubljanin E, Herteliu C, Hostiuc M, Hostiuc S, Jakovljevic M, Jozwiak JJ, Kissimova-Skarbek K, Król ZJ, **Kopec JA** et al. Changes in disease burden in Poland between 1990-2017 in comparison with other Central European countries: A systematic analysis for the Global Burden of Disease Study 2017. *PLoS One*. 2020 Mar 2;15(3):e0226766. doi: 10.1371/journal.pone.0226766. eCollection 2020.
56. Gauvreau A, Ajilil Y, Fournier F, Ratelle L, Gagnon E, Beaudreuil J, Petit-Teixeira E, Droit A, **Michou L**. Identification of rare genetic variants in the familial forms of Dupuytren's disease. *J Rheumatol*. 2020;47(7):1035.
57. GBD 2017 Colorectal Cancer Collaborators (**Kopec J** is one). The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Gastroenterol Hepatol*. 2019 Dec;4(12):913-933. doi: 10.1016/S2468-1253(19)30345-0. Epub 2019 Oct 21.
58. Goplen C, Beaupre L, Voaklander D, **Jones A**, Kung S. Preoperative opioid use negatively impacts one-year outcomes after total knee arthroplasty. Canadian Orthopaedic Residents' Symposium. (Montreal) June 19-22, 2019 <https://www.xcdsystem.com/coa/program/f96TB6S/index.cfm?pgid=764>.
59. Gkrouzman E, Sevim E, Finik J, Andrade D, Pengo V, Sciascia S, Tektonidou M, Ugarte A, Chighizola C, Belmont HM, Pérez Sanchez L, Ji Lanlan, **Fortin P**. Antiphospholipid antibody profile stability over time: prospective results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ("Registry"). *Arthritis Rheum*. 71(Suppl 10):3191-3193.

60. Gunay A, Davidson A, **Colmegna I, Lacaille D**, Loewen H, Meltzer M, Mengistu Y, Scuccimarri R, Yirsaw Z, Bernatsky S, Hitchon C. Safety of low-dose methotrexate in human immunodeficiency virus (HIV) infection. *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 970.
61. **Hahn T, Sayre E**, Goycochea-Robles MV, **Lacaille D**. Adherence to statin therapy in rheumatoid arthritis patients: a population-based cohort study. *Arthritis Rheum*. 71(Suppl 10):1668-1670.
62. Hahn T, **Sayre EC**, Goycochea-Robles M, **Lacaille D**. Adherence to statin therapy in rheumatoid arthritis patients: A population-based cohort study? *J Rheumatol*. 2020; 47(7):1073.
63. Hannan MT, **Backman CL**, Jones K. Must-read journal articles for rheumatology health professionals in 2019.
64. Hanly J, Li Q, Su L, Urowitz M, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, **Clarke AE**, Wallace DJ, Isenberg DA, Rahman A, Merrill J, **Fortin P**, Gladman D, Bruce I, Petri M, Ginzler EM, Dooley MA et al. Peripheral nervous system disease in systemic lupus erythematosus: results from an international inception cohort study. *Arthritis Rheum*. 71(Suppl 10):1152-53.
65. Hanson HM, Friesen J, Beaupre L, Jasper L, Millington J, **Jones CA**. Physical activity among older adults with osteoarthritis residing in rural environments: a qualitative study investigating perceptions of stakeholder groups. *Osteoarthritis and Cartilage* 2020;28(1): S168-S169.
66. Harkness T, Fu X, Zhang Y, **Choi HK**, Stone J, Blumenthal K, Wallace Z. Serum IgG4 concentrations differ according to race and sex. *Arthritis Rheum*. 71(Suppl 10):1694-96.
67. Hawker GA, Bohm E, Dunbar M, Faris P, **Jones CA**, Noseworthy T, Ravi B, Woodhouse L, Dick D, Paul P et al: Pre-operative predictors of the likelihood of achieving a composite measure of net benefit from total knee arthroplasty in people with knee osteoarthritis. *Osteoarthritis Cartilage*. 2020;28(1):S369-S370.
68. Herman A, Masri BA, Duncan CP, **Greidanus NV, Garbuz DS**. Multivariate analysis of risk factors for re-dislocation after revision for dislocation after total hip arthroplasty. *Hip Int*. 2020 Jan;30(1):93-100. doi: 10.1177/1120700019831628. Epub 2019 Mar 19.
69. Himmel M, Ye C, **Hudson M, Jamal S**, Saltman A. Acral digital ischemia associated with immune checkpoint inhibitor therapy: a case series of the Canadian Research Group of Rheumatology in Immuno-oncology (CANRIO) experience. *J Rheumatol*. 2020; 47(7):1051.
70. Ho K, Yao C, Novak Lauscher H, Koehler BE, **Shojania K, Jamal S**, Collins D, Kherani R, Meneilly G, Eva K. Remote assessment via video evaluation (RAVVE): a pilot study to trial video-enabled peer feedback on clinical performance. *BMC Med Educ*. 2019 Dec 18;19(1):466. doi: 10.1186/s12909-019-1905-3.

71. Holdren M, Schieir O, Bartlett SJ, Bessette L, Boire G, **Hazlewood G**, Hitchon C, Keystone E, Tin D, Thorne C, Bykerk V, Pope J and Canadian Early Arthritis Cohort (CATCH) Investigators. Maximal improvement in fatigue lags behind achievement of sustained remission in early rheumatoid arthritis. *Arthritis Rheum.* 71(Suppl 10):764-767.
72. Holdren M, Schieir O, **Bartlett S**, Bessette L, Boire G, **Hazlewood G**, Hitchon C, Keystone E, Tin D, Thorne C, Bykerk V, Pope J. Improvements in fatigue lags behind disease activity in early rheumatoid arthritis patients in sustained remission. *J Rheumatol.* 2020;47(7):1128-29.
73. **Hoque MR, Aviña-Zubieta JA, De Vera M**, Qian Y, **Esdaile J, Xie H**. Impact of antimalarial adherence on mortality among patients with systemic lupus erythematosus: A population-based study. *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 1025.
74. **Hoque R, Avina-Zubieta JA, De Vera MA**, Qian Y, **Esdaile JM, Xie H**. How antimalarials adherence affects the mortality of lupus patients? A population based study. *J Rheumatol.* 2020;47(7):1054.
75. **Hudson M**, Maltez N, Ivory C, Demery-Varin M. Cyclophosphamide for the treatment of skin fibrosis in systemic sclerosis: a systematic review. *Arthritis Rheum.* 71(Suppl 10):4598.
76. **Hunt MA, Charlton JM, Esculier JF**. Osteoarthritis year in review 2019: mechanics. *Osteoarthritis Cartilage.* 2020 Mar;28(3):267-274. doi: 10.1016/j.joca.2019.12.003. Epub 2019 Dec 23. Review.
77. Impellizzeri FM, Jones DM, Griffin D, Harris-Hayes M, Thorborg K, Crossley KM, Reiman MP, Scholes MJ, Ageberg E, Agricola R, Bizzini M, Bloom N, Casartelli NC, Diamond LE, Dijkstra HP, Di Stasi S, Drew M, Friedman DJ, Freke M, Gojanovic B, Heerey JJ, Hölmich P, **Hunt MA**, et al. Patient-reported outcome measures for hip-related pain: a review of the available evidence and a consensus statement from the International Hip-related Pain Research Network, Zurich 2018. *Br J Sports Med.* 2020 Feb 17. pii: bjsports-2019-101456. doi: 10.1136/bjsports-2019-101456. [Epub ahead of print].
78. Inman R, Garrido-Cumbrera M, **Chan J**, Cohen M, Debrum-Fernandes AJ, Gerhart W, Haroon N, Jovaisas A, Major G, Mallinson M, Rohekar S, Leclerc P, Schneiderman J, Rahman P. Factors associated with use of biological therapies for axial spondyloarthritis in Canada. Results from the IMAS survey. *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 1270.
79. Inman R, Garrido-Cumbrera M, **Chan J**, Cohen M, Brum-Fernandes A, Gerhart W, Haroon N, Jovaisas A, Mallinson M, Rohekar S, Leclerc P, Schneiderman J, Rahman P. Are work-related issues related to higher burden of disease in Canadian axSpA patients? Results from the IMAS Survey. *J Rheumatol.* 2020; 47(7):1045.
80. Jetha A, Tucker L, Bowring J, **Backman CL**, Proulx L, Kristman V, Hael EM, Perlin L, Gignac MAM. It starts at work: the relationship between workplace supports and presenteeism among young adults with rheumatic disease. *Arthritis Rheum.* 71(Suppl 10):3665.

81. Jetha A, Tucker L, Bowring J, **Backman CL**, Proulx L, Kristman V, Gignac MAM. Casting a wide net: comparing strategies for recruiting 18-35-year-olds with rheumatic disease as study participants. *Arthritis Rheumatol.* 71(Suppl 10):4269-70.
82. Johnson S, Brinks R, Costenbader K, **Clarke AE** et al. Performance of the EULAR/ACR 2019 performance of the classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 358.
83. **Jones A**, Kania-Richmond A, Ellis K, Robert J, Slomp M, Beaupre L. A GLAD® experience - evaluation of implementing a group-based osteoarthritis exercise program in Alberta, Canada. *Osteoarthritis Cartilage* 2020;28(1):S449.
84. Jorge A, **Lu N**, **Choi HK**, **Esdaile JM**, **Lacaille D**, **Aviña-Zubieta JA**. Hydroxychloroquine use and cardiovascular events among patients with systemic lupus erythematosus and rheumatoid arthritis. *Arthritis Rheum.* 2019;71(Suppl 10):1551-52.
85. Jorge A, **Lu N**, **Choi HK**. Opioid prescription use among patients with rheumatic disease: a population based cohort study. *Arthritis Rheum.* 71(Suppl 10):3606-08.
86. Jorge A, **Lu N**, **Choi HK**. Contemporary prescription opioid use and predictors among patients with systemic lupus erythematosus. *Arthritis Rheumatol.* 71(Suppl 10):4476-77.
87. Karacabeyli D, **Shojania K**, Dehghan N, **Lacaille D**. Obesity management and smoking cessation in rheumatoid arthritis: perceptions of rheumatology health care providers in British Columbia. *J Rheumatol.* 2020; 47(7):1109.
88. Kemp JL, Risberg MA, Mosler A, Harris-Hayes M, Serner A, Moksnes H, Bloom N, Crossley KM, Gojanovic B, **Hunt MA**, et al. Physiotherapist-led treatment for young to middle-aged active adults with hip-related pain: consensus recommendations from the International Hip-related Pain Research Network, Zurich 2018. *Br J Sports Med.* 2019 Nov 15. pii: bjsports-2019-101458. doi: 10.1136/bjsports-2019-101458. [Epub ahead of print].
89. Kim H, Lefebvre F, Hoa S, **Hudson M**. Mortality and morbidity in scleroderma renal crisis: a systematic literature review. *Arthritis Rheumatol.* 2019;71(Suppl 10):1241-1243.
90. King LK, Waugh EJ, Woodhouse L, Hawker GA, **Jones A**: What change in six-minute walk test indicates a clinically meaningful improvement in mobility to patients with knee osteoarthritis after total knee arthroplasty? *Osteoarthritis Cartilage* 2020;28(1):S81.
91. King LK, Waugh EJ, Woodhouse L, Hawker GA, **Jones A**: Improvement in walking in patients with cardiometabolic disease after total knee arthroplasty for osteoarthritis. *Osteoarthritis Cartilage* 2020;28(1):S356-S357.
92. King L, Waugh E, Woodhouse L, Hawker G, **Jones A**. Improvement in walking in patients with cardiometabolic disease after total knee arthroplasty for osteoarthritis. *J Rheumatol.* 2020; 47(7):1063.

93. King L, Waugh E, Woodhouse L, Hawker G, **Jones A**. What change in six-minute walk test indicates a clinically meaningful improvement in mobility to patients with knee osteoarthritis after total knee arthroplasty? *J Rheumatol*. 2020; 47(7):1063.
94. **Kopec JA, Cibere J, Lu N, Xie H, Aviña-Zubieta JA, Esdaile J**. Trends in prescribing of NSAIDs and opioids among osteoarthritis patients in British Columbia, Canada, 1998-2014. *Arthritis Rheum*. 2019;71(Suppl 10):3882-83.
95. **Kopec JA, Sayre EC, Okhmatovskaia A, Cibere J, Li L, Bansback N, Wong H, Esdaile J**. Impact of hypothetical changes in the use of analgesics on the burden of osteoarthritis: a population-based microsimulation study. *Arthritis Rheum*. 2019;71(Suppl 10):3883-84.
96. Krustev E, **Choi M**, Fritzler M, Jung M, **Barber C, Clarke A**. Clinical features associated with Anti-dsDNA, Anti-Sm, and hypocomplementemia within the Southern Alberta Registry for Lupus Erythematosus (STARLET). *J Rheumatol*. 2020; 47(7):1073.
97. Kummerle-Deschner JB, Sturm D, **Benseler S**. Tocilizumab – an effective rescue therapy for refractory unclassified autoinflammatory diseases in children. *Arthritis Rheum*. 71(Suppl 10):2145-46.
98. Kröber G, Weber U, Carmona R, Yeung U, **Chan J**, et al. The relative diagnostic utility of inflammatory back pain criteria in an inception cohort of patients with psoriasis, iritis, and colitis presenting with undiagnosed back pain. *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 1133.
99. Laaouad L, Roberts J, Ennis D, Ye C, Al jumaily K, **Hudson M, Jamal S**, Pope J, Nevskaya T, Saltman A, Himmel M, Fifi-Mah A, Tisseverasinghe A, Maltez N,, Colmegna I, Hoa S. Preexisting autoimmune disease and rheumatic immune-related adverse events associated with cancer immunotherapy: a case series from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO). *Arthritis Rheum*. 71(Suppl 10):3762-63.
100. Ladouceur A, **Clarke A**, Ramsey-Goldman R, Urowitz M, Hanly J, Gordon C, Petri M, Ginzler E, Wallace D, Bai SC, Romera-Diaz J, Dooley M, Peschken C, Isenberg D, Rahman A, Manzi S, Aranow C, Sanchez-Guerrero J, Gladman D, **Fortin P**, Merrill J, Khamashta M, Bruce I, Bernatsky S. Hematologic and non-hematologic cancer risk in a large inception SLE Cohort. *J Rheumatol*. 2020; 47(7):1073.
101. **Le CY, Whittaker JL**. How health outcomes differ between youth who suffer a traumatic, sport-related knee injury and matched controls; Implications for rehabilitation and understanding post-traumatic osteoarthritis risk. *Osteoarthritis Cartilage* 2020;28(1):S413-415.
102. **Le CY, Whittaker JL**. How do health outcomes differ between youth who have a recent sport-related knee injury and uninjured youth: Implications for medical management and post-traumatic OA risk? *Clin J Sport Med*. 2020;30(3):e117.
103. **Le CY, Whittaker JL**. Understanding quality of life after a youth sport-related knee injury. Canadian Bone and Joint Conference, Virtual (Zoom®), June 13, 2020 (Top Oral Presentation in Population and Community Health).

104. Lee C, Thomas M, Whittle S, Buchbinder R, Kamso M, Pardo J, **Hazlewood G**. Development and Pilot of Novel Process Using Machine Learning and Crowd-Sourcing to Conduct a Living Systematic Review of Rheumatoid Arthritis Drug Therapy. *J Rheumatol*. 2020; 47(7):1068.
105. Legge A, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, Romero-Diaz J, Sanchez-Guerrero J, Wallace DJ, Bernatsky S, **Clarke AE**, Merrill J, Ginzler EM, **Fortin P**, Gladman D, Urowitz M, Bruce I et al. Prediction of organ damage accrual in systemic lupus erythematosus using a frailty index. *Arthritis Rheum*. 71(Suppl 10):2867-2869.
106. **Li LC, Xie H, Lu N**, Shaw C, Gromala D, **Backman CL, Tam J**, Noonan G, **Aviña-Zubieta A, Hoens A, Townsend A, Feehan L**. Efficacy of a counselling program to promote physical activity in people with inflammatory arthritis. *Arthritis Rheum*. 71(Suppl 10): 438-39.
107. **Li LC, Xie H, Lu N**, Gromala D, Shaw C, **Backman CL, Tam J**, Noonan G, **Aviña-Zubieta JA, Hoens A, Townsend A, Feehan L**. Efficacy of a 3-month wearable-enabled physical activity counselling program for people with knee osteoarthritis. *Arthritis Rheum*. 71(Suppl 10): 4981-82.
108. **Li LY, Lu N, Kopec J, Esdaile J, Xie H, Aviña-Zubieta JA**. Trends in non-steroidal anti-inflammatory drugs (NSAIDs) and opioids among patients with systemic lupus erythematosus: a population-based study. *Arthritis Rheum*. 2019;71(Suppl 10):1889-1891.
109. **Li LY, Lu N, Sayre E, Xie H, Lacaille D, Esdaile J, Aviña-Zubieta JA**. The risk of venous thromboembolism in patients with psoriatic disease and rheumatoid arthritis, a population-based study. *Arthritis Rheum*. 71(Suppl 10):1415-17.
110. **Li LY, Xie H, Sayre E, Aviña-Zubieta JA**. Risk of cardiovascular disease associated with the use of glucocorticoids in patients with incident systemic lupus erythematosus: a population-based study. *Arthritis Rheum*. 71(Suppl 10):4939-41.
111. **Li LY, Lu N, Sayre E, Xie H, Lacaille D, Esdaile J, Aviña-Zubieta JA**. Risk of venous thromboembolism in rheumatoid arthritis patients initiating biologic and non-biologic DMARDs, a population-based study. *Arthritis Rheum*. 71(Suppl 10):3378-80.
112. **Li LY, Lu N, Xie H, Cibere J, Kopec J, Esdaile J, Aviña-Zubieta JA**. Association of tramadol with all-cause mortality, cardiovascular disease, venous thromboembolism and hip fractures among patients with osteoarthritis. A population-based study. *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 118.
113. Lim L, Cheung D, Mohamed K, **Lacaille D**, Pullenayegum EM, Hitchon C. Longitudinal work transitions in early inflammatory arthritis patients: are there targets for intervention to improve employment? *Arthritis Rheum*. 71(Suppl 10):2373-74.

114. Lim L, Cheung D, Mohammad K, **Lacaille D**, Pullenayegum E, Hitchon C. Longitudinal work transitions in early Inflammatory arthritis patients: are there targets for intervention to improve employment? *J Rheumatol.* 2020; 47(7):1057.
115. Liu X, **Barber CEH**, Bertazzon S, Patel AB, Mosher DP, Homik J, Katz S, Smith C, Robert J, **Marshall DA**. Rheumatoid arthritis prevalence, area-level indicators and geographical disparities: a spatial analysis approach.
116. **Lopatina E, Marshall D**, MacKean G, **Barber C**, Thorne C, Ahluwalia V, Mosher D, Zimmer M, Schieir O, Woolf A, Boire G, **Bartlett S**, Bessette L, **Hazlewood G**, Hitchon C, Keystone E, Pope J, Tin D, Bykerk V, CATCH Canadian Early Arthritis Cohort Study Investigators. Alignment of care delivery patterns for patients with inflammatory arthritis with the pan-Canadian approach to inflammatory arthritis models of care: a qualitative evaluation. *J Rheumatol.* 2020; 47(7):1114.
117. Lunden K, Inrig T, Paton M, Shupak R, Kennedy C, McGlynn M, **Barber C**. Measuring advanced /extended practice roles in arthritis and musculoskeletal care in Canada: stand up and be counted too (2)! *Arthritis Rheum.* 71(Suppl 10):420-21.
118. **Luquini A, Zheng Y, Xie H, Backman C, Rogers P, Kwok A, Knight A**, Gignac M, Mosher D, **Li L, Esdaile J**, Thorne C, **Lacaille D**. Effectiveness of the Making it Work™ program at improving presenteeism and work cessation in workers with inflammatory arthritis – results of a randomized controlled trial. *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 7.
119. **Luquini A, Zheng Y, Xie H, Backman C, Rogers P, Kwok A, Knight A**, Gignac M, Mosher D, **Li LC, Esdaile J**, Thorne C, **Lacaille D**. Effectiveness of the Making it Work™ program at improving presenteeism and work cessation in workers with inflammatory arthritis – results of a randomized controlled trial. *J Rheumatol.* 2020;47(7):1036.
120. **Ma JK**, Adamjee L, **Collins JA, Davidson E, English K, Hoens AM, Tsui K, McQuitty S, Sequeira L, Li LC**. Strength training for people with rheumatoid arthritis: barriers, facilitators, and tailoring considerations. *Arthritis Rheum.* 71(Suppl 10):3929-30.
121. **Ma JK, Leese J, Therrien S, Hoens AM, Tsui K, Li LC**. A scoping review of the state of strength training behaviour change interventions. *Ann behav med.* 2020;54 (Suppl 1):S1–S827.
122. Mahler M, Roup F, Bentow C, **Hudson M**, Baron M, **Choi M**, Fritzler M. Anti-RNPC-3 Antibodies are associated with nuclear speckled immunofluorescence pattern and enriched in triple negative systemic sclerosis patients. *Arthritis Rheum.* 71(Suppl 10):4645-47.
123. Mak A, Cheung M, Leong WYJ, Dharmadhikari B, Ye Kow N, Petri M, Manzi S, **Clarke A**, Aranow C, Arnaud L, Askanase A, Bae SC, Bernatsky S, Bruce I, **Fortin P** et al. Glucocorticosteroid usage and major organ damage in patients with systemic lupus erythematosus – meta-analyses of observational studies published between 1979 and 2018. *Arthritis Rheumatol.* 71(Suppl 10):4543-45.

124. Maksymowych WP, Carmona R, **Chan J**, Yeung J, Aydin SZ, Martin L, Masetto A, Mosher D, Ziouzina O, Keeling S, Rohekar S, Dadashova R, Paschke J, Carapellucci A, Lambert R. Description and prevalence of spondyloarthritis in unselected patients with psoriasis, acute anterior uveitis, and inflammatory bowel disease presenting with undiagnosed back pain. *Arthritis Rheum.* 71(Suppl 10):4421-23.
125. Maksymowych WP, Carmona R, **Chan J**, Yeung J, Aydin SZ, Martin L, Masetto A, Mosher D, Ziouzina O, Keeling S, Rohekar S, Dadashova R, Paschke J, Carapellucci A, Lambert R. What is the impact of MRI on the performance of the ASAS Classification criteria in patients presenting with undiagnosed back pain. *Arthritis Rheumatol.* 71(Suppl 10):1011-13.
126. Maksymowych WP, Carmona R, **Chan J**, Yeung J, Aydin SZ, Martin L, Masetto A, Mosher D, Ziouzina O, Keeling S, Rohekar S, Dadashova R, Paschke J, Carapellucci A, Lambert R. Performance of the ASAS classification criteria presenting with undiagnosed back pain: data from the screening in axial spondyloarthritis in psoriasis, iritis, and colitis cohort. *Arthritis Rheumatol.* 71(Suppl 10):1017-19.
127. Maksymowych WP, Carmona R, **Chan J**, Yeung J, Aydin SZ, Martin L, Masetto A, Mosher D, Ziouzina O, Keeling S, Rohekar S, Dadashova R, Paschke J, Carapellucci A, Lambert R. Enhanced performance of the ASAS classification criteria by deletion of non-discriminatory clinical items: data from the screening in axial spondyloarthritis in psoriasis, iritis, and colitis cohort. *Arthritis Rheumatol.* 71(Suppl 10):1019-20.
128. Maksymowych W, Carmona R, **Chan J**, Yeung J, Aydin S, Martin L, Masetto A, Mosher D, Ziouzina O, Keeling S, Rohekar S, Dadashova R, Paschke J, Carapellucci A, Lambert R. Enhanced performance of the ASAS Classification Criteria by deletion of non-discriminatory clinical items: Data from the Screening in Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis Cohort. *J Rheumatol.* 2020; 47(7):1048.
129. Maltez N, Puyade M, Lansiaux P, Wang M, Baron M, Colmegna I, Farge D, **Hudson M**. Longitudinal changes in health –related quality of life in systemic sclerosis treated with autologous hematopoietic stem cell transplant compared to standard of care. *Arthritis Rheumatol.* 71(Suppl 10):4595–4597.
130. Maltez N, Puyade M, Lansiaux P, Wang M, Baron M, **Colmegna I**, Farge D, **Hudson M**. Longitudinal changes in health-related quality of life in systemic sclerosis treated with autologous hematopoietic stem cell transplant compared to standard of care. *J Rheumatol.* 2020; 47(7):1088.
131. Maltez N, Demery M, Ivory C, **Hudson M**. Cyclophosphamide for the treatment of skin fibrosis in systemic sclerosis: a systematic review. *J Rheumatol.* 2020; 47(7):1088.
132. Manaseer TS, Gross DP, Dennett L, Schneider K, **Whittaker JL**. Gait deviations associated with concussion: A systematic review. *Clin J Sport Med.* 2020 Mar;30 Suppl 1:S11-S28. doi: 10.1097/JSM.0000000000000537.

133. **Marozoff S, McCormick N, Choi J, Choi H.** No causal association of serum urate or gout with Alzheimer's disease: A Mendelian randomization analysis. *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 219.
134. **Marshall DA,** Liu X, Katz S, Patel A, Bertazzon S, Mosher D, Homik J, Smith C, Robert J, **Barber C.** Geographic variation in the prevalence of rheumatoid arthritis in Alberta: a spatial analysis. *J Rheumatol.* 2020; 47(7):1038.
135. **Marshall DA,** Currie G, Lee R, Kennedy B, **Barber C,** Twilt M, **Benseler S,** Brose A, MacMullan P, Mosher D. The budget impact of a biosimilar transition policy for rheumatoid arthritis patients in Alberta. *J Rheumatol.* 2020; 47(7):1113.
136. **Mazzei D,** Ademola A, Abbott HJ, Sajobi T, Hildebrandt K, **Marshall DA.** Are exercise, education and diet interventions a cost-effective treatment to manage hip and knee osteoarthritis? A systematic review.
137. **McCormick N,** Wallace ZS, Sacks CA, Hsu J, **Choi HK.** Decomposition analysis of spending and price trends for biologic anti-rheumatic drugs in Medicare and Medicaid. *Arthritis Rheumatol.* 71(Suppl 10):4848-4850.
138. **McCormick N,** Wallace ZS, Yokose C, Jorge AM, Sacks CA, Hsu J, **Choi HK.** From a potential solution to part of the problem: analysis of spending and price trends for brand-name and generic colchicine and other gout medications. *Arthritis Rheumatol.* 71(Suppl 10):5137-5140.
139. **McCormick N, Lu N, Rai SK,** Yokose C, Zhang Y, **Choi HK.** Population impact attributable to modifiable risk factors for hyperuricemia and the fallacy of the variance explained. *Arthritis Rheumatol.* 71(Suppl 10):3658-61.
140. **McCormick N,** Choi J, **Marozoff S, Choi H.** Mendelian randomization shows no causal association between serum urate or gout and type-2 diabetes. *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 107.
141. McDermott G, Fu X, Stone J, Zhang Y, **Choi HK,** Wallace Z. Cigarette smoking is a risk factor for ANCA-associated vasculitis. *Arthritis Rheumatol.* 71(Suppl 10):1413-15.
142. Meyer A, Troyanov Y, Drouin J, Bourre-Tessier J, Oligny-Longpre G, Landon-Cardinal O, Hervier B, How S, Mansour AM, Rich E, Goulet JR, Chartrand S, **Hudson M,** Nehme J, Makhzoum JP, Zarka F, Hussein S et al. Treating statin-induced Anti-HMGCR myopathy with normal muscle strength: a new window of opportunity. *Arthritis Rheumatol.* 71(Suppl 10):629-30.
143. Meyer A, Leclair V, Landon-Cardinal O, Ellezam B, D'Aoust J, Giannini M, Geny B, Arnaud L, Gottenberg JE, Sibilia J, Satoh M, Frizler M, Troyanov Y, **Hudson M.** ACR/EULAR criteria for myositis and systemic sclerosis lack sensibility for scleromyositis. *Arthritis Rheumatol.* 71(Suppl 10):630-32.
144. Mori K, Prado CM, **Le CY, Whittaker JL.** Dietary intake in youth with a sport-related knee injury: Implications for secondary prevention of post-traumatic osteoarthritis. *Osteoarthritis Cartilage* 2020;28(1):S391-392.

145. Mosler AB, Kemp J, King M, Lawrenson PR, Semciw A, Freke M, Jones DM, Casartelli NC, Wörner T, Ishøi L, Ageberg E, Diamond LE, **Hunt MA**, et al. Standardised measurement of physical capacity in young and middle-aged active adults with hip-related pain: recommendations from the first International Hip-related Pain Research Network (IHiPRN) meeting, Zurich, 2018. *Br J Sports Med*. 2019 Dec 19. pii: bjsports-2019-101457. doi: 10.1136/bjsports-2019-101457. [Epub ahead of print].
146. Mrklas K, Barber T, Campbell-Sherer D, Green L, **Li L**, Marlett N, Miller J, Shewchuk B, Teare S, Wasylak T, **Marshall D**. Co-designing a mobile health App for patient and physician knee osteoarthritis management. *J Rheumatol*. 2020;47(7):1113-14
147. Nevskaya T, et al on behalf of Canadian Scleroderma Research Group (CSRG) Members: **Hudson M**, **Fortin PF**, et al. Cumulative incidence, survival and predictors of pulmonary hypertension in systemic sclerosis subsets: PAH is not increased in limited vs diffuse patients by adjusted competing risk analysis. *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 709.
148. Ogdie A, Love T, Takeshita J, Gelfand J, Scher J, **Choi H**, Fitzsimmons R, Ritchlin CT, Merola JF. Impact of biologic therapy on the incidence of PSA among patients with psoriasis. *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 769.
149. Oswald J, Barton KI, Smith E, **Mazzei D**, Richmond AK, Martin R, Schneider PS, **Marshall D**, Hart DA, **Whittaker JL**. A comparison between a standardized (GLA:DTM Canada) and an individualized (JointEffort) exercise program on functional mobility, quality of life, and pain management in knee osteoarthritis (OA) patients. *Clin J Sport Med*. 2020;30(3):e125.
150. Palmer D, Cooper D, Emery C, Batt M, Engebretson L, **Whittaker J**. Olympic-career related sports injury epidemiology: the retired Olympian musculoskeletal health study (ROMHS). *British Journal of Sports Medicine*; London Vol. 54, Iss. Suppl 1.
151. Park E, **Jones A**, Forhan M. Hearing patients' voices: Including patient perspectives for meaningful interactions. P 107. Abstr 275 <https://fourwaves-sots.s3.amazonaws.com/static/media/uploads/2019/06/28/isdm2019-oralsessionsbooklet-2019-06-28.pdf>
152. Paudel YR, Jhangri G, Feeny D, , Ikert C, Slaughter S, **Jones A**. Construct validity of Health Utilities Index Mark 2 and 3 among residents in long-term care facilities. *Quality of Life Research* 2019; 28(Suppl 1): S165.
153. Pham T, Currie G, Twilt M, IZjerman M, Kip M, Hull PM, **Hazlewood G**, **Benseler S**, **Marshall DA** for the UCAN CURE Investigators. Physician perspectives on tapering biologics in Juvenile Idiopathic Arthritis: A qualitative analysis.
154. Pianarosa E, Hsiao R, Thomas M, Linkert T, **Hazlewood G**, **Barnabe C**. Supporting equity through rheumatoid arthritis treatment guidelines: the development of logic models for six populations at risk for inequitable outcomes in Canada. *J Rheumatol*. 2020;47(7):1083-84.

155. Pianarosa E, **Chomistek K**, Hsiao R, Anwar S, **Hazlewood G**, **Barnabe C**. Global rural and remote patients with rheumatoid arthritis: A systematic review of disease epidemiology, clinical outcomes and health service utilization. *J Rheumatol*. 2020;47(7):1083.
156. Powell M, Bykerk V, Schieir O, Valois MF, **Bartlett SJ**, Bessette L, Boire G, Hitchon C, Keystone E, Pope J, Thorne C, Tin D, **Hazlewood G**. Patterns of sustained remission and subsequent DMARD tapering in early rheumatoid arthritis: data from the Canadian Early Arthritis Cohort. *Arthritis Rheum*. 71(Suppl 10):2323-2326.
157. Rahman P, Arendse R, Fortin I, Chow A, Khraishi M, Kapur S, Zummer M, Kherani R, **Chan J**, Rampakakis E, Rachich M, Asin-Milan O, Lehman A, Nantel F. Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in psoriatic arthritis patients from a prospective observational registry. *Arthritis Rheumatol*. 71(Suppl 10):2481-82.
158. Rahman P, Garrido-Cumbrera M, Rohekar S, Mallinson M, Major G, Jovaisas A, Haroon N, Gerhart W, Fernandes A, Cohen M, **Chan J**, Leclerc P, Schneiderman J, Inman R. The patient journey towards diagnosis of axial spondyloarthritis in Canada: results from the IMAS survey. *J Rheumatol*. 2020;47(7):1045.
159. Rahman P, Garrido-Cumbrera M, Rohekar S, **Chan J**, et al. Characterizing the impact of axial spondyloarthritis on daily life: Gender and patient-reported outcomes associated with functional limitation in Canada results from the IMAS survey. *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 1274.
160. Raisanen AM, **Whittaker JL**, Toomey CM, Pasanen K, Emery CA. On the road to prevention of early osteoarthritis: Development of an exercise intervention. *Clin J Sport Med*. 2020;30(3):e109.
161. Räsänen AM, Emery CA, Toomey CM, Pasanen K, **Whittaker JL**. Development of the online SHRED Osteoarthritis program. Canadian Bone and Joint Conference, Virtual (Zoom®), June 13, 2020
162. **Rebic N**, Ellis U, **De Vera M**. "Walking into the unknown..." Key challenges of family planning and pregnancy in inflammatory arthritis: a systematic review and thematic synthesis of qualitative studies. *J Rheumatol*. 2020;47(7):1121-22.
163. Reich K, **Dutz J**, Foley P, Thaçi D, Vender R, Song M, Miller M, You Y, Li S, Shen YK, Armstrong A. Four-year efficacy and safety of guselkumab in psoriasis patients with and without psoriatic arthritis: A pooled analysis from VOYAGE 1 and VOYAGE 2. *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 1673.
164. Reiman MP, Agricola R, Kemp JL, Heerey JJ, Weir A, van Klij P, Kassarian A, Mosler AB, Ageberg E, Hölmich P, Warholm KM, Griffin D, Mayes S, Khan KM, Crossley KM, Bizzini M, Bloom N, Casartelli NC, Diamond LE, Di Stasi S, Drew M, Friedman DJ, Freke M, Gojanovic B, Glyn-Jones S, Harris-Hayes M, **Hunt MA**, et al. Consensus recommendations on the classification, definition and diagnostic criteria of hip-related pain in young and middle-aged active adults from the International Hip-related Pain Research Network, Zurich 2018. *Br J Sports Med*. 2020 Jan 20. pii: bjsports-2019-101453. doi: 10.1136/bjsports-2019-101453. [Epub ahead of print]

165. Roberts J, Ennis D, **Hudson M**, Ye C, Saltman A, Hoa S, Pope J, Himmel M, Maltez N, Fifi-Mah A, Tisseverasinghe A, Rottapel R, Al Jumaily K, Ly C, Cartagena L, **Jamal S**. Rheumatic immune related adverse events associated with cancer immunotherapy: a nationwide multi-centre Canadian cohort from the Canadian Research Group of Rheumatology in Immuno-oncology (CanRIO). *Arthritis Rheumatol*. 71(Suppl 10):3793-95.
166. Ruel-Gagné S, Simonyan D, Légaré J, Bessette L, **Fortin PR, Lacaille D**, Dogba MJ, **Michou L**. Expectations and educational needs of rheumatologists and rheumatology fellows in the field of precision medicine in Canada. *J Rheumatol*. 2020; 47(7):1091.
167. Salma J, Yamamoto S, **Jones CA**. Older immigrant adults' experiences and perceptions of physical activity. *Osteoarthritis Cartilage*. 2020;28(1):S165.
168. **Salmasi S**, Kelly A, **Bartlett SJ**, De Wit M, March L, Tong A, Tugwell P, Tymms K, Verstappen S, **De Vera M**. Researchers' perspectives on adherence intervention research and outcomes in rheumatology: An international qualitative study. *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 520.
169. Schieir O, **Bartlett SJ**, Valois MF, Bessette L, Boire G, **Hazlewood G**, Hitchon C, Keystone E, Pope J, Thorne C, Tin D, Bykerk V, and Canadian Early Arthritis Cohort (CATCH) Investigators. Real-world remission outcomes in the first year following RA diagnosis vary considerably with the Disease Activity Index used and a sizable proportion have persistent active disease across all measures: results from the Canadian Early Arthritis Cohort (CATCH). *Arthritis Rheumatol*. 71(Suppl 10):2087-2089.
170. Schieir O, Valois MF, **Bartlett S**, Bessette L, Boire G, **Hazlewood G**, Hitchon C, Keystone E, Tin D, Thorne C, Pope J, Bykerk V, CATCH Canadian Early arthritis Cohort. Estimating "Real-World" unmet needs for achieving remission in the first year following rheumatoid arthritis diagnosis: results from the Canadian Early Arthritis Cohort (CATCH). *J Rheumatol*. 2020; 47(7):1133.
171. Sevim E, Zisa D, Andrade D, Pengo V, Sciascia S, Tektonidou M, Ugarte A, Gerosa M, Belmont HM, Lopez-Pedrerera R, Ji L, **Fortin P**, Efthymiou M, and on behalf of APS ACTION et al. The clinical and laboratory characteristics of antiphospholipid antibody positive patients included in the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ("Registry"). *Arthritis Rheumatol*. 71(Suppl 10):191-93.
172. Schieir O, **Bartlett SJ**, Valois MF, Bessette L, Boire G, **Hazlewood G**, et al. Estimating real-world unmet needs for reaching remission in the first year following early RA diagnosis: Results from the Canadian early arthritis cohort (CATCH). *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 954.
173. Schieir O, **Hazlewood G, Bartlett SJ**, et al. How often does reaching target miss the mark: Longitudinal patterns of remission in real world early rheumatoid arthritis patients? *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 580.

174. Simon T, Suissa S, Skovron M, Frisell T, Askling J, Michaud K, Pedro S, Strangfeld A, Boers M, **Lacaille D**, Hochberg M, Gomez A. Solid tumor outcomes in patients with RA treated with abatacept and other DMARDs: results from a 10-year international observational study. *J Rheumatol.* 2020; 47(7):1071-72.
175. **Szlachetka T, Li L**, Liu-Ambrose T, **Xie H, Sayre E, Lacaille D**. Determinants of cognitive function in rheumatoid arthritis patients. *Arthritis Rheum.* 71(Suppl 10):4070-71.
176. Ta V, Schieir O, Valois MF, **Hazlewood G, Bartlett SJ**, et al. More than half of newly diagnosed RA patients are not convinced of the necessity of RA medicines: Associations with RA characteristics, symptoms, and function in the Canadian Early Arthritis Cohort (CATCH). *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 584.
177. Taghavi M, Barbhaya M, Tektonidou M, **Fortin P**, Andrade D, Knight J, Artim-Esen B, Atsumi T, Cohen H, Ji L, Sciascia S et al. Descriptive analysis of biopsy-proven antiphospholipid antibody-associated nephropathy patients included in the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ("Registry"). *Arthritis Rheumatol.* 71(Suppl 10):3194-96.
178. Tan J, Bardi M, **Lacaille D**. A case of fibroblastic rheumatism. *J Rheumatol.* 2020; 47(7):1137.
179. Tatangelo M, Tomlinson G, Keystone E, Paterson M, **Bansback N**, Bombardier C. The effect of rheumatoid arthritis and biologics on the acquisition of subsequent diseases and adverse events: a matched longitudinal population study. *Arthritis Rheumatol.* 71(Suppl 10):5140-42.
180. Tatangelo M, Tomlinson G, Paterson JM, **Bansback N**, Keystone E, Bombardier C. The association of rheumatoid arthritis with health care costs from the payer's perspective from 2001-2015. *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 508.
181. Thorne C, Craig M, Tin D, Schieir O, Valois MF, Dittmar C, Ng E, Aubrey M, Samadi N, Bykerk V, **Hazlewood G**. Real-world treatment patterns with methotrexate over a decade (2007-2017): Durability of initial subcutaneous optimal dosing demonstrated in a large single-center interprofessional early rheumatoid arthritis clinic. *J Rheumatol.* 2020; 47(7):1068-69.
182. **To-Miles F**, Forwell S, Puterman E, **Collins JA, Leblanc K, Backman C**. The health-promoting potential of everyday activities: Preliminary results from an exploratory study of adults with and without inflammatory arthritis. *Arthritis Rheumatol.* 71(Suppl 10):3666-67.
183. Toomey CM, Emery CA, **Whittaker JL**. The longitudinal change in knee injury and osteoarthritis outcome score (KOOS) in youth and youth adults at risk of post-traumatic knee osteoarthritis compared to uninjured matched controls. *Osteoarthritis Cartilage* 2020;28:S370.

184. Toupin April K, Stinson J, Huber AM, Couchman D, Sachs H, Sivakumar A, Ragusa M, El Hindi T, Gaboury I, Duffy CM, Morgan EM, Brosseau L, **Li LC**, Brinkman W, Bisch M, Cohen J, Stringer E, Légaré F, Proulx L, Cavallo S, **Fortin PR**, Tugwell P. Preliminary acceptability testing of a decision support intervention for youth with juvenile idiopathic arthritis and their parents. Oral presentation at the 2019 International Shared Decision Making Conference, Quebec city, Canada, July 7-10, 2019.
185. **Truong LK**, Mosewich AD, Miciak M, Pajkic A, **Li LC**, **Whittaker JL**. Balancing return to sport and a functional knee, exploring the perceptions of exercise therapy and physical activity of youth 1-2 years after a sport-related ACL injury. *Osteoarthritis Cartilage* 2020;28:S160-161.
186. **Truong LK**, Mosewich AD, Miciak M, Pajkic A, **Li L**, **Whittaker JL**. Balancing return to sport and a functional knee: Exploring the perceptions of exercise therapy and physical activity of youth 1-2 years after a sport-related ACL injury. *Clin J Sport Med*. 2020;30(3):e115.
187. Urowitz M, Gladman D, Su J, Farewell V, Sanchez-Guerrero J, Romero-Diaz J, Bae SC, **Fortin P**, Nived O, **Clarke AE**, Bernatsky S, Gordon C, Hanly J, Wallace DJ, Isenberg DA, Rahman A, Merrill J et al. Incidence and predictors of atherosclerotic vascular events in a multicenter inception systemic lupus erythematosus cohort. *Arthritis Rheumatol*. 71(Suppl 10):2804-06.
188. Uy C, Chedrawe M, Chivukula P, Wade J, Wong S, Nimmo M, Bardi M, Carruthers R, **Carruthers M**. Autoimmune encephalitis and related disorders are not rare in British Columbia. *J Rheumatol*. 2020; 47(7):1138.
189. Van Dyk J, Heard B, **Barnabe C**. Principal component analysis identifies unique sub-populations in rheumatoid arthritis using a combination of serological biomarkers: a cross sectional study. *Arthritis Rheumatol*. 71(Suppl 10):754-756.
190. Wallace Z, Fu X, Zhang Y, Stone J, **Choi HK**. The association of reduced low-density lipoprotein (LDL) cholesterol levels with ANCA-associated vasculitis (AAV). *Arthritis Rheumatol*. 71(Suppl 10):3004-05.
191. Wallace Z, Yun H, Curtis J, Yang S, Chen L, Stone J, **Choi HK**. ANCA-Associated Vasculitis Management in the United States: data from the RISE registry. *Arthritis Rheumatol*. 71(Suppl 10):1512-13.
192. Wallace Z, Fu X, Harkness T, Stone J, Zhang Y, **Choi HK**. Causes of death in ANCA-associated vasculitis according to ANCA type. *Arthritis Rheumatol*. 71(Suppl 10):1874-76.
193. Wallace Z, Harkness T, Fu X Stone J, **Choi HK**. Treatment delays associated with prior authorization for infusible medications; a cohort study. *Arthritis Rheumatol*. 71(Suppl 10):5020-23.
194. Wallace Z, Harkness T, Blumenthal K, **Choi HK**. Increasing capacity and reducing costs of rituximab administration. *Arthritis Rheumatol*. 71(Suppl 10):495-97.
195. Wallwork R, Harkness T, Fu X, Perugino C, **Choi HK**, Stone J, Wallace Z. Early mortality in IgG4-related disease. *Arthritis Rheumatol*. 71(Suppl 10):626-28.

196. Wang L, Miloslavsky E, Stone J, **Choi HK**, Zhou L, Wallace Z. A retrospective cohort study using clinical notes and latent topic modeling to characterize the natural history of ANCA-associated vasculitis. *Arthritis Rheumatol.* 71(Suppl 10):2992-95.
197. Wang Q, Eltit F, **Garbuz D**, Duncan C, Masri B, **Greidanus N**, Wang R. CoCrMo metal release in metal-on-highly crosslinked polyethylene hip implants. *J Biomed Mater Res B Appl Biomater.* 2019 Aug 19. doi: 10.1002/jbm.b.34470. [Epub ahead of print]
198. Weber U, Kröber G, Carmona R, Yeung J, **Chan J**, et al. ASAS modification of the Berlin algorithm and the DUET algorithm for diagnosing axial spondyloarthritis: Results from the screening in axial spondyloarthritis for psoriasis, iritis and colitis cohort. *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 734.
199. Weiler M, Schieir O, Valois MF, **Bartlett SJ**, Bessette L, Boire G, **Hazlewood G**, et al. Real-world predictors of starting different advanced DMARD treatments in rheumatoid arthritis: A prospective investigation from the Canadian Early Arthritis Cohort Group. *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 995.
200. Westby M, Koehn C, Lui M, **Kerr S**. Patient informed feasibility testing of two methods to assess quality of rehabilitation care after total joint replacement surgery for osteoarthritis. *J Rheumatol.* 2020; 47(7):1115.
201. **Whittaker JL**. Osteoarthritis Year in Review: Rehabilitation. *Osteoarthritis Cartilage* 2020;28(1):S4-14 (Plenary).
202. Widdifield J, Bernatsky S, Pope JE, Ahluwalia V, **Barber CEH**, Eder L, Kuriya B, Ling V, Paterson M, Thorne JC. Encounters with rheumatologist in a publicly funded Canadian healthcare system: a population-based study. *J Rheumatol.* 2019 Epub ahead of print.
203. Yokose C, **Rai S**, **Lu N**, **McCormick N**, Curhan G, **Choi HK**. The effects of a low-fat, Mediterranean, or low-carbohydrate diet on serum urate. *Arthritis Rheumatol.* 71(Suppl 10):1561-64.
204. Yokose C, Eide S, Simeone J, **Shojania K**, Nicolaou S, Becce F, **Choi HK**. Frequently encountered artifacts in novel application of dual-energy CT to vascular imaging: a pilot study. *Arthritis Rheumatol.* 71(Suppl 10):2021-23.
205. Yokose C, Lu N, Chen-Xu M, **McCormick N**, Pillinger M, Zhang Y, **Choi HK**. Subtypes of gout based on comorbidity patterns among black patients in the US general population – Cluster Analysis of the National Health and Nutrition Examination Survey 2007-2016. *Arthritis Rheum.* 71(Suppl 10):552-555.
206. Yokose C, Jorge A, D'Silva K, Serling-Boyud N, Matza M, Nasrallah M, Keller S, Oza A, **Choi HK**, Bolster M, Collier D. Using electronic visits (E-Visits) to achieve goal serum urate levels in patients with gout in a rheumatology practice: a pilot study. *Arthritis Rheumatol.* 71(Suppl 10):3316-3319.

207. Yoshida K, Lin TC, Wei MY, Malspeis S, Chu SH, Camargo C, Raby B, **Choi HK**, Tedeschi SK, Barbaiya M, Lu B, Costenbader K, Karlson E, Sparks J. Accrual of multimorbidity after incident rheumatoid arthritis and matched comparators using a large prospective cohort with 30 years of follow-up. *Arthritis Rheumatol.* 71(Suppl 10):276-78.
208. **Zhao K, Xie H, Li LY, Esdaile J, Avina-Zubieta JA.** Risk of severe infections and mortality in patients with new diagnosis of systemic lupus erythematosus. A population-based study. *J Rheumatol.* 2020;47(7):1075.
209. Zheng B, Wang M, Fritzler M, **Choi M**, Baron M, **Hudson M.** Systemic sclerosis auto-antibody profiles predict interstitial lung disease onset but not progression. *Arthritis Rheumatol.* 71(Suppl 10):2936-38.
210. Zheng B, Nevskaya T, Baxter CA, Ramey DR, Pope JE, Baron M; **Fortin PR**, Canadian Scleroderma Research Group . Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity. *Rheumatology (Oxford).* 2019 Jul 29. pii: kez299. doi: 10.1093/rheumatology/kez299. [Epub ahead of print].
211. Zheng B, Wang M, Fritzler M, Choi M, Baron M, **Hudson M**, Canadian Scleroderma Research Group (CSRG). Systemic sclerosis auto-antibody profiles predict interstitial lung disease onset but not progression. *J Rheumatol.* 2020;47(7):1131.
212. **Zheng Y, Xie H, Aviña-Zubieta JA, Yazdani K, Esdaile JM, Lacaille D.** The socioeconomic, gender, urban-rural, and regional disparities in the risk of acute myocardial infarction among rheumatoid arthritis patients. *Arthritis Rheum.* 71(Suppl 10):1966-68.
213. **Zheng Y, Xie H, Li L, Esdaile J, Aviña-Zubieta JA.** Regional variation in cardiovascular disease among SLE patients. *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 1059.
214. **Zhou Y, Lu N, Esdaile J, Xie H.** Trends of total joint arthroplasty among patients with osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS) in British Columbia Canada, 1998-2013. *Ann Rheum Dis*, volume 79, supplement 1, year 2020, page 1258.
215. Zhou W, Murray T, Cartagena L, Lim H, Schaeffer D, Slack G, Skinnider B, Irvine R, Chang S, **Carruthers M**, Chen L. IgG4-related disease as a mimicker of malignancy. *J Rheumatol.* 2020;47(7):1137.